Clinical trial register · Spain

Clinical Trials in Barcelona, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746

Trials with a site in Barcelona

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Active, closed

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

NCT06307431Renal Cell Carcinoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

272

Madrid, Barcelona, Seville

2024-04-10

Recruiting

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438Non-Small Cell Lung Cancer

DrugsLivmoniplimab·Budigalimab·Pemetrexed·Cisplatin

AbbVie

Phase 2/3

840

Santiago de Compostela, L'Hospitalet de Llobregat, Barcelona, Madrid, Valencia

2024-04-10

Active, closed

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764Non-Muscle Invasive Bladder Neoplasms

DrugsTAR-200·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

272

Badalona, Barcelona, Madrid, Málaga, Sabadell, Santander, Seville, Valencia

2024-04-09

Active, closed

An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency

NCT06255782Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Ornithine Carbamoyltransferase Deficiency (Disorder), Urea Cycle Disorders, Inborn

iECURE, Inc.

Phase 3

Barcelona, Madrid

2024-04-08

Recruiting

Immunological Reset to Allow Access to HLA Compatible Transplantation in Highly Sensitized Kidney Transplant Candidates Through Non-myeloablative Autologous Stemm Cell Transplantation

NCT06809075Kidney Disease, Kidney Transplant, Kidney Transplant Candidates

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

Barcelona

2024-04-05

Recruiting

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

NCT06276491Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor

DrugXmAb541

Xencor, Inc.

Phase 1

282

Barcelona, Madrid, Pamplona

2024-04-04

Active, closed

Comparison Between Optical Coherence Tomography and Intravascular Ultrasound for Intermediate Left Main Coronary Artery Lesions

NCT06272643Coronary Disease

Fundación EPIC

Observational

153

Alicante, Aravaca, Barcelona, Cadiz, Córdoba, El Palmar, Gijón, Huelva

2024-04-04

Active, closed

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease

DrugPirfenidone

Avalyn Pharma Inc.

Phase 2

375

Granada, Barcelona, Santander, Madrid, Málaga, Oviedo, Seville, Cadiz

2024-04-03

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

L'Hospitalet de Llobregat, Santiago de Compostela, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Barcelona, Madrid

2024-04-03

Active, closed

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT06305247Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer

Ipsen

Phase 1/2

Barcelona, Madrid

2024-04-03

Recruiting

Implementing an Adapted Smoke-free Homes Intervention in Spain

NCT06932276Secondhand Tobacco Smoke Exposure Reduction, Smoking Prevention

Institut Català d'Oncologia

Not applicable

408

Barcelona

2024-04-02

Active, closed

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

NCT05708235Breast Cancer

DrugsGiredestrant·Inavolisib·Abemaciclib

MedSIR

Phase 2

976

A Coruña, Alicante, Barcelona, Bilbao, Castellon, Córdoba, Elche, Girona

2024-04-01

Recruiting

Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients

NCT06044623Metastatic Breast Cancer, Advanced Breast Cancer, Quality of Life, Toxicity

Region Örebro County

Phase 3

495

Barcelona

2024-04-01

Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

NCT06265727Solid Tumor, Adult

DrugsCRB-701·Anti-PD-1

Corbus Pharmaceuticals Inc.

Phase 1/2

348

Barcelona, Madrid, Valencia

2024-04-01

Active, closed

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767Bladder Cancer

DrugsIntismeran autogene·Enfortumab Vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

230

Badalona, Pozuelo de Alarcón, Madrid, Barcelona, Seville

2024-03-28

Active, closed

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT06220201Multiple Sclerosis, Myasthenia Gravis

DrugsZola-cel·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

120

Barcelona, Madrid, Valencia

2024-03-28

Recruiting

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

NCT06163430Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia

Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1/2

180

Barcelona, Las Palmas, Madrid, Zaragoza

2024-03-26

Recruiting

Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype

NCT06269900Hospital Acquired Pneumonia

DrugDexamethasone

Nantes University Hospital

Phase 3

450

Barcelona

2024-03-26

Recruiting

Safe-Infusion Study

NCT06727240Intravenous Access, Medical Device

Interlinked AB

Not applicable

548

Barcelona

2024-03-25

Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT06253871HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer

Iambic Therapeutics, Inc

Phase 1

383

Barcelona, Madrid, Málaga, Seville, Valencia

2024-03-25

Active, closed

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

NCT06333808HIV-1-infection

DrugsBictegravir·B/F/TAF·Lenacapavir

Gilead Sciences

Phase 3

577

Badalona Barcelona, Barcelona, Madrid, Seville, Valencia

2024-03-25

Recruiting

Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry

NCT05914441Purpura, Thrombocytopenic

Fundación Española de Hematología y Hemoterapía

Observational

300

Seville, L'Hospitalet de Llobregat, Barcelona, Guadalajara, Madrid, Murcia, Valencia

2024-03-22

Recruiting

Is the 3D-PANC MSP Model Superior to CT for Assessing Response to Neoadjuvant Treatment in PCA Patients?

NCT06582342Adenocarcinoma of the Pancreas

Fundación para la Investigación del Hospital Clínico de Valencia

Observational

Alicante, Badajoz, Barcelona, Candelaria, Castellon, Málaga, Murcia, Palma de Mallorca

2024-03-21

Recruiting

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

NCT06256588Neoplasms, Head and Neck

DrugDostarlimab

GlaxoSmithKline

Phase 3

864

BaracaldoVizcaya, Barcelona, Cartagena Murcia, HebrOn, Jerez de la Frontera, L'Hospitalet de Llobrega, Lugo, Madrid

2024-03-21

Active, closed

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

NCT06268886Alzheimer Disease, Early Onset

DrugMoponetug

Bristol-Myers Squibb

Phase 2

310

Barcelona, Sant Cugat del Vallès, Lleida

2024-03-20

Active, closed

Plan to Evaluate Early Endothelialization of a Polymer Free Sirolimus-eluting Coronary Stent System (VIVO ISARTM) Compared With Everolimus-eluting Durable Polymer Stent (XIENCE SkypointTM) in Patients Undergoing Percutaneous Coronary Intervention.

NCT06214819Coronary Artery Disease

Fundación EPIC

Not applicable

Barcelona, Girona, L'Hospitalet de Llobregat

2024-03-20

Active, closed

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

NCT06041386Asthma

DrugMepolizumab

GlaxoSmithKline

Phase 4

336

Barcelona, Girona, Valencia

2024-03-20

Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781Low Grade Serous Ovarian Cancer

DrugsAvutometinib·Defactinib·Pegylated liposomal doxorubicin·Anastrozole

Verastem, Inc.

Phase 3

270

El Palmar, Donostia / San Sebastian, Barcelona, Córdoba, Madrid, Santiago de Compostela, Valencia

2024-03-18

Recruiting

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan

NCT06236269Breast Cancer Stage IV

DrugSacituzumab Govitecan

SOLTI Breast Cancer Research Group

Phase 2

Badalona, L'Hospitalet de Llobregat, Barcelona, Granada, Madrid, Reus, Seville, Valencia

2024-03-15

Recruiting

Association of Ultrasound Features of the Myometrium Suggestive of Adenomyosis and Clinical Symptoms

NCT07397715Adenomyosis of Uterus

Swiss GO Trial Group

Observational

1,000

Barcelona

2024-03-15

Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

DrugPegozafermin

89bio, Inc.

Phase 3

1,350

Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pontevedra, Santander, Santiago de Compostela

2024-03-13

Recruiting

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT05939414Oligometastatic Prostate Cancer (OMPC)

DrugsPiflufolastat·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

450

Granada, L'Hospitalet de Llobregat, Barcelona, El Palmar, Madrid, Seville, Valencia

2024-03-12

Recruiting

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

NCT06378190Refractory B-Cell Lymphoma, B-cell Lymphoma Recurrent

Instituto de Investigación Biomédica de Salamanca

Phase 1/2

Barcelona, L'Hospitalet de Llobregat, Madrid, El Palmar, Pamplona, Salamanca, Seville

2024-03-11

Active, closed

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

NCT06220604Plaque Psoriasis

DrugsIcotrokinra·Deucravacitinib

Janssen Research & Development, LLC

Phase 3

731

Alcorcón, Badalona, Barcelona, Manises, Salamanca, Santiago de Compostela, Seville, Villajoyosa

2024-03-09

Active, closed

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

NCT06318273Metastatic Castration-Resistant Prostate Cancer

AbbVie

Phase 1

152

Barcelona, Madrid, Seville

2024-03-08

Recruiting

Evaluation of Endothelial Glycocalyx in the Surgical Resuscitation of Major Burn Patients

NCT06670248Syndecan 1, Severe Burn, Endotheliopathy of Trauma, Endothelial Glycocalyx

Hospital Universitari Vall d'Hebron Research Institute

Observational

Barcelona

2024-03-05

Active, closed

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm

Eli Lilly and Company

Phase 1

490

Barcelona, Madrid, Seville

2024-03-05

Active, closed

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

DrugLepodisiran

Eli Lilly and Company

Phase 3

17,300

A Coruña, Alcorcón, Badalona, Barcelona, Córdoba, Denia, El Palmar, Murcia, Ferrol

2024-03-05

Active, closed

A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD

NCT05643638Graft Versus Host Disease, Acute

Cynata Therapeutics Limited

Phase 2

Barcelona, Madrid, Murcia, Pamplona

2024-03-04

Active, closed

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer

DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib

AstraZeneca

Phase 3

594

Barcelona, Madrid, Ourense, Santander, Seville

2024-03-04

By invitation

Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy

NCT06138743Myotonic Dystrophy 1

Sarepta Therapeutics, Inc.

Phase 1/2

Almería, Barcelona, Madrid

2024-03-04

Recruiting

Postoperative Recovery in Elderly Patients Assessed With QoR-15E

NCT07505758Postoperative Recovery in Elderly Patients, Quality of Recovery After Elective Surgery, Perioperative Care Outcomes in Older Adults

Hospital Universitari Vall d'Hebron Research Institute

Observational

600

Barcelona

2024-03-04

Active, closed

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

NCT05737628Lymphoma

DrugsBYON4228·Rituximab

Byondis B.V.

Phase 1

Barcelona, Madrid

2024-03-04

Recruiting

Cognitive and Metacognitive Evaluation in VR-Based Avatar Therapy for Psychosis

NCT07091344Schizophrenia Disorders, Treatment Resistant Hallucinations

Fundació Sant Joan de Déu

Not applicable

Barcelona

2024-03-01

Recruiting

Precision Medicine for L/GCMN and Melanoma 1

NCT06608420Melanoma (Skin Cancer), Nevi and Melanomas

Fundacion Clinic per a la Recerca Biomédica

Observational

6,000

Barcelona

2024-03-01

Recruiting

"Multicenter Registry for Chest Wall Reconstruction Using Custom Dynamic Prostheses (PRODIPET)"

NCT07018960Chest Wall Tumors, Post-traumatic Syndrome, Malignant Bone Tumor of Chest Wall

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Not applicable

Cruces, Las Palmas de Gran Canaria, Barcelona, Madrid, Alzira

2024-03-01

Recruiting

Effect of CPAP Treatment in Patients With Severe Uncontrolled Asthma: The ASTHMA-SLEEP Trial

NCT06314477Obstructive Sleep Apnea, Asthma

Hospital Clinic of Barcelona

Not applicable

138

Barcelona

2024-02-29

Active, closed

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

NCT06335173Alzheimer Disease

Acumen Pharmaceuticals

Phase 2

542

Sant Cugat del Vallès, Cuarte de Huerva, Barcelona, Donostia / San Sebastian, Getxo, Madrid, Seville, Valencia

2024-02-29

Recruiting

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT05935215Atypical Hemolytic Uremic Syndrome

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

Santiago Compostela, Barcelona, Córdoba, Málaga, Seville, Valencia

2024-02-28

Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025Solid Cancer

DrugsR-DXd·Topotecan·Paclitaxel

Daiichi Sankyo

Phase 2/3

860

Barcelona, Jaén, Madrid, Pamplona, Valencia

2024-02-27

Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 2

740

Barcelona, Madrid, Málaga, Seville, Valencia

2024-02-26

Recruiting

Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites

NCT05056220Decompensated Cirrhosis and Ascites

DrugHuman albumin

Aleksander Krag

Phase 3

240

Barcelona

2024-02-26

Active, closed

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

NCT06239467Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation

DrugsAtirmociclib·Tucatinib·Ribociclib·Fulvestrant

OnKure, Inc.

Phase 1

200

Barcelona, Madrid

2024-02-26

Recruiting

SNV1521 in Participants With Advanced Solid Tumors

NCT06220864Advanced Solid Tumor

DrugsDB-1310·Abiraterone·Darolutamide

Synnovation Therapeutics, Inc.

Phase 1

400

Barcelona, Madrid

2024-02-23

Recruiting

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06001788AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar

DrugsXospata·Granulocyte Colony-Stimulating Factor·Ziftomenib·Idarubicin

Kura Oncology, Inc.

Phase 1

171

Barcelona, Oviedo, Seville, Valencia

2024-02-22

Active, closed

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

NCT05925530Non-small Cell Lung Cancer

DrugDurvalumab

AstraZeneca

Phase 2

142

Barakaldo, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Valencia, Zaragoza

2024-02-22

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

NCT05979311HIV, HIV Infections

DrugsBictegravir·Dolutegravir·Emtricitabine·Lamivudine

ViiV Healthcare

Phase 3

307

Badalona, Barcelona, Elche Alicante, La Laguna-Tenerife, Madrid, Marbella, Palma de Mallorca, Valencia

2024-02-21

Active, closed

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

NCT06012435Carcinoma, Non-Small-Cell Lung

DrugsSigvotatug vedotin·Docetaxel

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

762

Palma, A Coruña, Barcelona, Alicante, Badalona, Castellon, Madrid, Málaga

2024-02-21

Recruiting

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

NCT06283966COPD (Chronic Obstructive Pulmonary Disease)

AstraZeneca

Phase 3

5,250

Alicante, Badia Del Vallès, Barakaldo, Barcelona, Castro Urdiales, Córdoba, Granada, Madrid

2024-02-21

Active, closed

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 3

404

Málaga, Seville, Zaragoza, Las Palmas de Gran Canaria, Badalona, Barcelona, Santiago de Compostela, Majadahonda

2024-02-20

Active, closed

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

NCT06206837Breast Cancer

DrugsVepdegestrant·Atirmociclib

Pfizer

Phase 1/2

Barcelona, Lleida, Madrid, Seville

2024-02-19

Active, closed

Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

NCT05930275Crohn's Disease

AbbVie

Observational

1,200

Sant Joan Despí, Jerez de la Frontera, Córdoba, Las Palmas de Gran Canaria, Leganés, Oviedo, Galdakao, Barcelona

2024-02-19

Recruiting

Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

NCT05933057Duchenne Muscular Dystrophy

DrugHydroxyurea

Italfarmaco

Phase 3

138

Barcelona, Valencia

2024-02-19

Recruiting

Telemonitoring Utility in the Process of Adaptation to Home Mechanical Ventilation (HMV)

NCT06240637Non Invasive Ventilation

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Not applicable

Barcelona

2024-02-17

Active, closed

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

NCT05907096Delayed Graft Function

DrugEmpasiprubart

argenx

Phase 2

103

Badalona, Barcelona, Granada, L'Hospitalet de Llobregat, Valencia, Zaragoza

2024-02-17

Active, closed

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140Carcinoma, Non-Small-Cell Lung

DrugsClobetasol·Minocycline·Chlorhexidine·Clindamycin

Janssen Research & Development, LLC

Phase 2

305

A Coruña, Alicante, Barcelona, Jaén, Lugo, Madrid, Málaga, Seville

2024-02-16

By invitation

Optimal Positive End-Expiratory Pressure in Robotic-Assisted Thoracic Surgery Without Capnothorax

NCT06784037Robotic Thoracic Surgery, Mechanical Ventilation, Positive End Expiratory Pressure (PEEP)

Hospital Clinic of Barcelona

Observational

Barcelona

2024-02-16

Recruiting

Aurora Test for ART Donor Patients (AURORA-Donor)

NCT06280677Infertility

Fertiga, Belgium

Observational

160

Barcelona

2024-02-16

Recruiting

Study on Post-acute Myocardial Infarction Ventricular Defect: Outcome Evalutation in Relation to Surgical Timing

NCT06799780Myocardial Infarction (MI), Heart Disease

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

100

Barcelona

2024-02-12

Active, closed

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574Lung Cancer, Non-squamous, Non-small Cell

DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin

Boehringer Ingelheim

Phase 3

428

A Coruña, Alicante, Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia

2024-02-09

Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575Multiple Myeloma

DrugsElotuzumab·Elranatamab·Carfilzomib·Pomalidomide

Pfizer

Phase 3

492

Badalona, Terrassa, Barakaldo, Barcelona, Murcia, Girona, Valencia, Madrid

2024-02-08

Recruiting

Study of Olverembatinib (HQP1351) in Patients With CML-CP

NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase

DrugsBosutinib·Olverembatinib

Ascentage Pharma Group Inc.

Phase 3

333

Badalona, Barcelona, Elche, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Murcia

2024-02-05

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744Follicular Lymphoma (FL)

DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine

Genmab

Phase 3

1,095

Badalona, L'Hospitalet de Llobregat, Santander, Pamplona, Barcelona, Cáceres, Madrid, Salamanca

2024-02-05

Active, closed

Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus

NCT06333483Systemic Lupus Erythematosus

DrugObecabtagene autoleucel

Autolus Limited

Phase 1

Barcelona, Valencia

2024-02-02

Active, closed

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

NCT05853575Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung

DrugAdagrasib

Mirati Therapeutics Inc.

Phase 2

200

Santiago de Compostela, Málaga, Palma de Mallorca, Oviedo, Barcelona, Madrid, Seville, Valencia

2024-02-01

Recruiting

E-Emotio Project A Gamified Preventive School-based Paradigm Using Virtual Reality Technologies for Improving Emotional Regulation in Children and Adolescents.

NCT06236919Emotional Regulation, Virtual Reality, Anxiety, Depression

Universitat Internacional de Catalunya

Not applicable

160

Barcelona

2024-02-01

Active, closed

A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease

NCT06150820Pompe Disease (Late-onset)

Astellas Gene Therapies

Not applicable

119

Albacete, Barcelona, Donostia / San Sebastian, L'Hospitalet de Llobregat, Madrid, Valencia

2024-02-01

Recruiting

Immunological Reset to Enable Access to Hla-compatible Kidney Transplantation in Highly Sensitized Patients (RESET)

NCT07607197Kidney Failure, Chronic, Kidney Transplantation, Alloimmunization, HLA Sensitization

Hospital Universitari Vall d'Hebron Research Institute

Phase 1/2

Barcelona

2024-02-01

Recruiting

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

NCT05916313Glioma

DrugObrixtamig

Boehringer Ingelheim

Phase 1

Barcelona, Madrid

2024-01-30

Active, closed

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06212999Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

617

Alicante, Badalona, Barcelona, Granada, Las Palmas de Gran Canaria, Madrid, Manises, Pontevedra

2024-01-30

Recruiting

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

NCT05902169Glioblastoma, Recurrent Glioblastoma, GBM

DrugsLomustine·Temodal·Temozolomide·Carboplatin

CarThera

Phase 3

560

Barcelona, Madrid, Seville

2024-01-29

Recruiting

Accelerating Referral for Thrombectomy in Acute Stroke Patients Using an Artificial Intelligence-based Software

NCT06741332Stroke, Stroke Acute, Ischemic Stroke, Acute, Thrombectomy

Hospital Universitari Vall d'Hebron Research Institute

Observational

250

Granollers, Barcelona

2024-01-27

Active, closed

Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection

NCT05527418Recent HIV-1 Infection

DrugDasatinib

Eva Bonfill

Phase 2

Barcelona

2024-01-26

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

NCT06004245Advanced Solid Tumors, Colorectal Cancer

DrugsVVD-133214·Avastin·Keytruda·Bevacizumab

Vividion Therapeutics, Inc.

Phase 1

280

Barcelona, Madrid, Pamplona, Valencia

2024-01-25

Active, closed

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

NCT06225596Metastatic Urothelial Cancer

DrugsZelenectide pevedotin·Avelumab·Gemcitabine·Cisplatin

BicycleTx Limited

Phase 2

375

Barcelona, Las Palmas de Gran Canaria, Madrid, Pamplona, San Sebastián, Santander, Santiago de Compostela, Valencia

2024-01-24

Active, closed

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

NCT06143891Chronic Graft Versus Host Disease

DrugsBelumosudil·Prednisolone·Prednisone

Sanofi

Phase 3

260

Santander, Barcelona, Madrid, Málaga, Salamanca, Seville, Valencia

2024-01-23

Recruiting

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

NCT06179069SCLC

DrugsZL-1310·Atezolizumab·Carboplatin

Zai Lab (Shanghai) Co., Ltd.

Phase 1

339

Barcelona, Madrid, Seville, Valencia, Málaga, Pozuelo de Alarcón

2024-01-23

Active, closed

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

NCT06132113Neuroendocrine Neoplasms

DrugsObrixtamig·Etoposide·Cisplatin·Carboplatin

Boehringer Ingelheim

Phase 1

Barcelona, Madrid

2024-01-22

Active, closed

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150Multiple Myeloma

DrugsElotuzumab·Talquetamab·Velcade·Teclistamab

Janssen Research & Development, LLC

Phase 3

838

Asturias, Barcelona, Burgos, Cáceres, Donostia / San Sebastian, Granada, Lugo, Madrid

2024-01-22

Recruiting

Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure

NCT06676696Renal Failure , Chronic, Graft Failure, Graft Rejection, Allograft

Hospital Universitari Vall d'Hebron Research Institute

Phase 4

202

Barcelona

2024-01-22

Active, closed

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

NCT06163326Vitiligo

DrugRitlecitinib

Pfizer

Phase 3

394

Córdoba, Barcelona, Las Palmas de Gran Canaria, Madrid

2024-01-19

Active, closed

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337Metastatic Breast Cancer

DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel

DualityBio Inc.

Phase 3

541

Barcelona, Sant Cugat del Vallès, Santiago de Compostela, Madrid, Majadahonda, Pozuelo de Alarcón, Málaga, Pamplona

2024-01-18

Recruiting

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed

Revolution Medicines, Inc.

Phase 1/2

616

Madrid, Pamplona, Valencia, A Coruña, Barcelona, Málaga, Seville

2024-01-18

Recruiting

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

NCT06130553Advanced Solid Tumors That Are MTAP Deficient

DrugsAZD3470·Dato-DXd

AstraZeneca

Phase 1/2

334

Barcelona, Madrid

2024-01-18

Recruiting

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197Heart Failure, Acute Heart Failure

DrugsKerendia·Finerenone

Colorado Prevention Center

Phase 3

5,200

Villamartín, Zaragoza, Badalona, Sanlúcar de Barrameda, A Coruña, Santiago de Compostela, Pamplona, Barcelona

2024-01-17

Active, closed

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

NCT06143878Plaque Psoriasis

DrugsIcotrokinra·Deucravacitinib

Janssen Research & Development, LLC

Phase 3

774

Alicante, Barakaldo, Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Valencia

2024-01-17

Not yet open

First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma

NCT06097455Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma

Fundacion Clinic per a la Recerca Biomédica

Early Phase 1

Santiago de Compostela, Barcelona, Madrid, Murcia, Oviedo, Palma de Mallorca, Salamanca

2024-01-15

Active, closed

A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4

NCT06246513Limb-girdle Muscular Dystrophy

Sarepta Therapeutics, Inc.

Phase 3

Barcelona

2024-01-15

Recruiting

Prospective, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Endovascular Treatment in Patients With Cerebral Aneurysms Using P64 and P48 Flow-Diverter Stents

NCT06201598Cerebral Aneurysm, Thromboembolic Disease

Hospital Universitario Central de Asturias

Observational

100

A Coruña, Badalona, Barcelona, Burgos, Donostia / San Sebastian, Madrid, Málaga, Oviedo

2024-01-12

Active, closed

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

NCT06183931Transthyretin Amyloid Cardiomyopathy

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,181

A Coruña, Barcelona, El Palmar, Jaén, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga

2024-01-11

Active, closed

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

NCT06109272Hepatocellular Carcinoma

DrugsLivmoniplimab·Budigalimab·Tremelimumab·Atezolizumab

AbbVie

Phase 2/3

Santander, Majadahonda, Barcelona, Córdoba, Madrid, Seville, Zaragoza

2024-01-11

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsErbitux·Cetuximab

AVEO Pharmaceuticals, Inc.

Phase 3

410

Alicante, Badalona, Barcelona, Cadiz, Madrid, Málaga, Santander, Valencia

2024-01-11

Active, closed

RZ358 Treatment for Congenital Hyperinsulinism

NCT06208215Congenital Hyperinsulinism

Rezolute

Phase 3

Barcelona, Seville

2024-01-11

Recruiting

Oxytocin Plus Self-compassion Training in Borderline Personality Disorder

NCT07551882Self-compassion Training (SCT) Plus Intranasal Oxytocin, Self-compassion Training (SCT) Plus Intranasal Placebo

DrugIntranasal oxytocin

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Phase 2

Barcelona

2024-01-10

Recruiting

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

NCT06840119Cancer, HLA-A*02:01-positive

Immunocore Ltd

Phase 1/2

600

Barcelona, Madrid

2024-01-10

Recruiting

Study to Verify the Efficacy of a Product Containing 125 mg of TetraSOD® for the Treatment of Male Infertility

NCT06324071Male Infertility

Fitoplancton Marino, S.L.

Not applicable

Barcelona

2024-01-08

Recruiting

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

NCT06174987Advanced Cancer, Metastatic Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 3

A Coruña, Barcelona, Distrito de Les Corts, L'Hospitalet de Llobregat, Madrid

2024-01-05

Recruiting

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

NCT06191263Acute Myeloid Leukemia

DrugsRVU120·Venetoclax

Ryvu Therapeutics SA

Phase 2

Barcelona, Cáceres, Madrid, Málaga, Pamplona, Seville, Valencia

2024-01-05

Active, closed

PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717

NCT06153966Prion Disease

Ionis Pharmaceuticals, Inc.

Phase 1/2

Barcelona

2024-01-04

Active, closed

Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

NCT05928390Post-Bariatric Hypoglycemia

RECORDATI GROUP

Phase 2

Barcelona, Córdoba, Girona, Madrid

2024-01-04

Recruiting

Applying a Multidisciplinary Intervention for Drug Adequacy in an Intermediate Care Hospital (AMIDA-ICH)

NCT07015112Poly Pharmacy, Frail Elderly

Parc Sanitari Pere Virgili

Not applicable

300

Barcelona

2024-01-04

Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

NCT06179160Solid Tumors

DrugsGEMNabP·INCB161734·INCA33890·Retifanlimab

Incyte Corporation

Phase 1

710

Barcelona, Madrid

2024-01-04

Active, closed

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy

NCT06280209Duchenne Muscular Dystrophy

DrugBMN 351

BioMarin Pharmaceutical

Phase 1/2

Barcelona, Seville

2024-01-03

Active, closed

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

NCT05849298Prostatic Neoplasm

DrugsARPI·Pylarify·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 2

L'Hospitalet de Llobregat, Barcelona, Madrid

2024-01-03

By invitation

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

NCT06191315Wheezing, Asthma

DrugDupilumab

Sanofi

Phase 3

Santiago de Compostela, Barcelona, Esplugues de Llobregat, Sabadell, Jerez de la Frontera, Madrid, Valencia

2024-01-03

Active, closed

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

NCT06079281Hypophosphatasia

DrugALXN1850

Alexion Pharmaceuticals, Inc.

Phase 3

124

Barcelona, Granada, Madrid, San Cristóbal de La Laguna, Santander, Vitoria-Gasteiz

2024-01-03

Recruiting

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

NCT07159750Migraine, Episodic Migraine, Chronic Migraine, Headache

Hospital Universitari Vall d'Hebron Research Institute

Observational

700

Badalona, Barcelona, L'Hospitalet de Llobregat, Mollet del Vallès, Viladecans, Albacete, Madrid, Zaragoza

2024-01-02

Recruiting

Self-guided Acceptance and Commitment Therapy-based Digital Smartphone Application for Management of Fibromyalgia

NCT05962437Fibromyalgia

Fundació Sant Joan de Déu

Not applicable

360

Barcelona, Sant Boi de Llobregat

2024-01-01

Recruiting

Impact of the Implementation of a Telemedicine Program on Patients Diagnosed with Asthma

NCT06116292Asthma, Telemedicine, Adherence, Treatment, Quality of Life

Hospital Universitari de Bellvitge

Not applicable

108

Barcelona

2024-01-01

Recruiting

Understanding the Transition from Normal Melanocytes to Nevus to Melanoma

NCT06605417Congenital Melanocytic Nevi, Melanoma, Skin, Nevi and Melanomas

Fundacion Clinic per a la Recerca Biomédica

Observational

100

Barcelona

2024-01-01

Recruiting

Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA)

NCT06379945Myelodysplastic Syndromes

Instituto de Investigación Biomédica de Salamanca

Observational

300

Badalona, Barcelona, Pamplona, Salamanca

2024-01-01

Recruiting

Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants

NCT06556446Ischemic Stroke

Insel Gruppe AG, University Hospital Bern

Observational

2,800

Barcelona

2024-01-01

Recruiting

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

NCT06190899mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease

DrugsGedatolisib·Darolutamide

Celcuity Inc

Phase 1/2

Barcelona, Madrid, Valencia

2024-01-01

Active, closed

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879Essential Thrombocythemia

DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib

Merck Sharp & Dohme LLC

Phase 3

340

Badalona, L'Hospitalet Del Llobregat, Barcelona, Santiago de Compostela, Madrid, Marbella, Albacete, Málaga

2023-12-31

Recruiting

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

NCT05950945Breast Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 3

250

Barcelona, Donostia / San Sebastian, Granada, Las Palmas de Gran Canaria, Madrid, Majadahonda, Murcia, Pamplona

2023-12-30

Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma

DrugsGolcadomide·Mosunetuzumab·Epcoritamab·Truxima

Bristol-Myers Squibb

Phase 1/2

460

Málaga, Barcelona, Madrid, Pamplona, Salamanca

2023-12-29

Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)

DrugSurovatamig

AstraZeneca

Phase 1/2

255

Barcelona, Madrid, Salamanca, Valencia

2023-12-29

Recruiting

Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment

NCT06247085Homocystinuria

DrugPegtibatinase

Travere Therapeutics, Inc.

Phase 3

Barcelona, Madrid, Santiago de Compostela, Seville

2023-12-28

Recruiting

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

NCT06149286Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

DrugsOdronextamab·Lenalidomide·Rituximab

Regeneron Pharmaceuticals

Phase 3

580

Santiago de Compostela, Palma, L'Hospitalet de Llobregat, Santander, Pozuelo de Alarcón, Oviedo, Barcelona, Granada

2023-12-28

Recruiting

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential

Orchestra BioMed, Inc

Not applicable

316

Badalona, Barcelona, Madrid, Santa Cruz de Tenerife

2023-12-27

Active, closed

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT06141486Multiple Sclerosis

DrugFrexalimab

Sanofi

Phase 3

943

Murcia, Barcelona, Barakaldo, L'Hospitalet de Llobregat, Donostia / San Sebastian, Girona, Las Palmas de Gran Canaria, Lleida

2023-12-27

Recruiting

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

NCT05280314Melanoma, Squamous Cell Carcinoma of Head and Neck

DrugsIO102-IO103·Pembrolizumab KEYTRUDA

IO Biotech

Phase 2

Barcelona, Madrid, Valencia

2023-12-21

Recruiting

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin

Eli Lilly and Company

Phase 3

1,264

A Coruña, Badajoz, Barakaldo, Barcelona, Hospitalet, Jerez de la Frontera, Las Palmas de Gran Canaria, León

2023-12-21

Active, closed

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

NCT06140836Carcinoma, Non-Small-Cell Lung

DrugsRepotrectinib·Crizotinib

Bristol-Myers Squibb

Phase 3

190

A Coruña, Santiago de Compostela, Barcelona, Madrid, Majadahonda, Málaga, Seville, Valencia

2023-12-21

Active, closed

Proof of Concept Study on Pitolisant Effect on Autism Spectrum Disorders in Children and Adolescents

NCT05953389Autism Spectrum Disorder

DrugPitolisant

Bioprojet

Phase 2

Barcelona, Burgos

2023-12-20

Recruiting

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

NCT05912517Hemolytic Disease of the Fetus and Newborn

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

120

Barcelona, Madrid, Seville

2023-12-20

Recruiting

PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

NCT05581121Cervical Carcinoma, Adenocarcinoma, Adenosquamous Carcinoma

Institut Claudius Regaud

Phase 3

510

Barcelona, Girona, Madrid

2023-12-20

Recruiting

Danon Disease Natural History Study

NCT06214507Danon Disease

Rocket Pharmaceuticals Inc.

Observational

Majadahonda, Barcelona

2023-12-20

Recruiting

Global Trial in APG2575 for Patients With CLL/SLL

NCT06104566CLL/SLL

DrugLisaftoclax

Ascentage Pharma Group Inc.

Phase 3

400

Barcelona, Palma de Mallorca, Santander, Valencia

2023-12-20

Active, closed

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

NCT05948475Cholangiocarcinoma

DrugTinengotinib

TransThera Sciences (Nanjing), Inc.

Phase 3

200

Barcelona, Córdoba, Madrid, Pamplona, Santiago de Compostela, Zaragoza

2023-12-20

Recruiting

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

NCT05828511Multiple Myeloma

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 1/2

149

Badalona, Pozuelo de Alarcón, Pamplona, Oviedo, Alicante, Barcelona, Madrid, Salamanca

2023-12-19

Recruiting

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

NCT06016920HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC

DrugsKeytruda·Pembrolizumab

Nykode Therapeutics ASA

Phase 1/2

110

Barcelona, Madrid

2023-12-19

Recruiting

Antibody-mediated LGI1 Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Chronic Phase of the Disease

NCT06515106Limbic Encephalitis With LGI1 Antibodies

Fundacion Clinic per a la Recerca Biomédica

Not applicable

Barcelona

2023-12-18

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga

Merck Sharp & Dohme LLC

Phase 3

1,314

Sabadell, Barcelona, Girona, A Coruña, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Burgos, Málaga

2023-12-18

Active, closed

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

DrugZipalertinib

Taiho Oncology, Inc.

Phase 3

285

Barcelona, A Coruña, Madrid, Málaga, Jaén

2023-12-18

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788Non-small Cell Lung Cancer (NSCLC)

DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

Jerez de la Frontera, A Coruña, Pozuelo de Alarcón, Málaga, Valencia, Barcelona, Madrid, Santa Cruz de Tenerife

2023-12-15

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Badalona, Barcelona, Jaén, Madrid, Valencia

2023-12-14

Recruiting

A Study of JNJ-87890387 for Advanced Solid Tumors

NCT06178614Neoplasms, Advanced Solid Tumors

Janssen Research & Development, LLC

Phase 1

200

Barcelona, Madrid

2023-12-14

Active, closed

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

NCT05734105GIST

DrugsRipretinib·Sunitinib

Deciphera Pharmaceuticals, LLC

Phase 3

Barcelona, Vigo, Valencia, Madrid, Oviedo, Seville

2023-12-13

Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsNemtabrutinib·Ibrutinib·Acalabrutinib

Merck Sharp & Dohme LLC

Phase 3

1,200

L'Hospitalet Del Llobregat, Barcelona, Pozuelo de Alarcón, Majadahonda, San Cristóbal de La Laguna, Salamanca

2023-12-13

Recruiting

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin

AstraZeneca

Phase 2

226

Barcelona, Madrid

2023-12-13

Active, closed

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

NCT06141473Multiple Sclerosis

DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab

Sanofi

Phase 3

1,655

Murcia, Barcelona, Barakaldo, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Pontevedra, Seville, Córdoba

2023-12-13

Recruiting

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugNexiguran ziclumeran

Intellia Therapeutics

Phase 3

1,200

A Coruña, Barcelona, Majadahonda, Málaga, Palma de Mallorca

2023-12-13

Recruiting

INtensity of OVarian Stimualtion and Euploid Embryos

NCT06154083Fertility

Fundación Santiago Dexeus Font

Phase 4

110

Barcelona

2023-12-12

Recruiting

The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)

NCT05763953Paroxysmal Supraventricular Tachycardia

Milestone Pharmaceuticals Inc.

Phase 2

Barcelona, Madrid

2023-12-11

Active, closed

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06132256Idiopathic Pulmonary Fibrosis

DrugAxatilimab

Syndax Pharmaceuticals

Phase 2

145

L'Hospitalet de Llobregat, Sabadell, Santander, Majadahonda, Oviedo, Barcelona, Cadiz, Girona

2023-12-11

Active, closed

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586Type 1 Diabetes Mellitus

DrugFrexalimab

Sanofi

Phase 2

197

Barcelona, Esplugues de Llobregat, Oviedo, Seville, Málaga, Valencia, Vitoria-Gasteiz

2023-12-11

Recruiting

Trial Comparing Conventional Antibiotic Strategies Versus Regimens Guided by Epidemiological Surveillance in Infected Patients With Cirrhosis (SURVIC_STUDY)

NCT05783661Decompensated Cirrhosis, Bacterial Infections

Eva Bonfill

Phase 4

198

Barcelona

2023-12-11

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

NCT06253130Advanced Solid Tumor

Eikon Therapeutics

Phase 1/2

156

Sabadell, Madrid, Pamplona, Barcelona, Seville, Valencia

2023-12-11

Active, closed

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

DrugsGiredestrant·Abemaciclib·Ribociclib·Palbociclib

Hoffmann-La Roche

Phase 3

1,050

Badalona, Jerez de la Frontera, Pozuelo de Alarcón, EL Palmar (EL Palmar), Vigo, Barcelona, Huelva, Jaén

2023-12-11

Active, closed

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243Chronic Inducible Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

362

Santiago, Granada, Barcelona, Alicante, Madrid, Valencia

2023-12-07

Active, closed

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958Endometrial Cancer

DrugsAbraxane·Adriamycin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

710

L'Hospitalet de Llobregat, Girona, Madrid, Valencia, Barcelona, Córdoba

2023-12-06

Active, closed

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT06077760Non-small Cell Lung Cancer

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

868

L'Hospitalet de Llobregat, Pozuelo de Alarcón, Majadahonda, Málaga, Barcelona, Seville

2023-12-06

Active, closed

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT06007690Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma

DrugBel-sar

Aura Biosciences

Phase 3

108

Barcelona, Santiago de Compostela, Seville, Valencia

2023-12-06

Active, closed

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

NCT06139406Lymphoma, Non-Hodgkin

DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543

Janssen Research & Development, LLC

Phase 1

Barcelona, Madrid, Pamplona, Salamanca

2023-12-06

Recruiting

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients

NCT06317805Pulmonary Arterial Hypertension

AOP Orphan Pharmaceuticals AG

Phase 4

110

Barcelona, Madrid

2023-12-06

Recruiting

Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery

NCT06246136Open Angle Glaucoma

Elios Vision, Inc.

Not applicable

194

Barcelona, Madrid

2023-12-05

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

NCT06188520ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)

DrugsCamizestrant·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 1/2

564

Barcelona, Pamplona, Valencia

2023-12-05

Active, closed

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Teysuno·Capecitabine

AstraZeneca

Phase 3

760

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Santander

2023-12-04

Active, closed

A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

NCT06514807Essential Thrombocythaemia

DrugBesremi

AOP Orphan Pharmaceuticals AG

Phase 3

117

Badalona, Barcelona, Madrid, Murcia

2023-12-04

Active, closed

BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

NCT06205706Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma

DrugPembrolizumab

BioInvent International AB

Phase 1/2

Barcelona, Madrid, Seville

2023-12-04

Recruiting

The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)

NCT06408441Epithelioid Hemangioendothelioma, Sarcoma,Soft Tissue

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Observational

100

Barcelona, Madrid

2023-12-01

Active, closed

Attempted Suicide Intervention Treatment and Prevention (SAMIT Program)

NCT06238414Suicide, Attempted, Suicide Prevention

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

Barcelona

2023-12-01

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NCT06215716NASH With Fibrosis, MASH With Fibrosis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

1,650

Sabadell, Santander, Majadahonda, Valencia, Barcelona, Madrid, Seville

2023-12-01

Recruiting

The Fourth Left Atrial Appendage Occlusion Study

NCT05963698Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism

Hamilton Health Sciences Corporation

Not applicable

4,000

Vigo, Alicante, Barcelona, Huelva, León, Madrid, Valladolid

2023-11-30

Recruiting

Safety And Performance Of Disc Care To Prevent Lumbar Disc Herniation Recurrence

NCT06023719Disc Herniation, Disk Herniated Lumbar

NEOS Surgery

Not applicable

L'Hospitalet de Llobregat, Madrid, Barcelona, San Cristóbal de La Laguna

2023-11-30

Recruiting

Randomized Study of Physiological vs Right Ventricular Pacing in Patients With Normal Ventricular Function Post TAVI

NCT06197503Transcatheter Aortic Valve Implantation, Physiological Pacing, Right Ventricular Pacing, AV Block

Hospital Clinic of Barcelona

Not applicable

Barcelona

2023-11-30

Recruiting

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

NCT06299748Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

DrugEfgartigimod

argenx

Observational

279

Barcelona

2023-11-30

Active, closed

Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors

NCT06150183Advanced Malignant Solid Tumor

DrugBNT314

BioNTech SE

Phase 1

Barcelona, Madrid, Pamplona

2023-11-30

Active, closed

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

NCT05988073Multifocal Motor Neuropathy

argenx

Observational

413

Alicante, Badalona, Barcelona, Bilbao, L'Hospitalet de Llobregat, Oviedo, Pamplona, San Sebastián

2023-11-29

Active, closed

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

NCT06113445NonSegmental Vitiligo

DrugPovorcitinib

Incyte Corporation

Phase 3

467

Alcorcón, Badalona, Barcelona, Madrid, Manises

2023-11-29

Active, closed

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

NCT06116786Carcinoma, Non-small-Cell Lung

DrugsJNJ-86974680·Cetrelimab

Johnson & Johnson Enterprise Innovation Inc.

Phase 1

Barcelona, Madrid, Valencia

2023-11-27

Recruiting

Conduction System Pacing vs Biventricular Pacing in Systolic Dysfunction and Wide QRS: Mortality, Heart Failure Hospitalization or Cardiac Transplant

NCT06105580Cardiac Resynchronization Therapy, Heart Failure

Hospital Clinic of Barcelona

Not applicable

320

Barcelona

2023-11-27

Active, closed

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

NCT06173531Hyperphagia in Prader-Willi Syndrome

DrugCarbetocin

ACADIA Pharmaceuticals Inc.

Phase 3

170

Barcelona, Madrid, Málaga

2023-11-27

Recruiting

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

NCT05948943Lymphatic Malformations

DrugAlpelisib

Novartis Pharmaceuticals

Phase 2/3

232

Palma, Esplugues, L'Hospitalet de Llobregat, A Coruña, Barcelona, Madrid

2023-11-24

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864Breast Cancer

DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 3

625

Barcelona, Granada, Hospitalet deLlobregat, Madrid, Pamplona, Santander

2023-11-23

Active, closed

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

NCT06282978Multiple Myeloma in Relapse

DrugElranatamab

PETHEMA Foundation

Phase 2

Santiago de Compostela, Palma de Mallorca, Badalona, Santander, Jerez de la Frontera, Las Palmas de Gran Canaria, El Palmar, Barcelona

2023-11-23

Recruiting

Cardioinhibitory Reflex Syncope. Permanent Pacemaker Therapy or Cardioneuroablation?

NCT05855603Reflex Syncope

Institut d'Investigació Biomèdica de Bellvitge

Not applicable

Sant Joan d'Alacant, Castellon, Vigo, Barcelona, Girona, Santa Cruz de Tenerife, Valencia, Zaragoza

2023-11-22

Active, closed

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491Metastatic Castration-Sensitive Prostate Cancer

DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate

AstraZeneca

Phase 3

1,898

Barcelona, Córdoba, L'Hospitalet de Llobregat, Lugo, Madrid, Sabadell, Valencia

2023-11-21

Recruiting

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma

DrugsLeucovorin·Adrucil·Oxaliplatin·Bevacizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 1

914

L'Hospitalet de Llobregat, Barcelona, Esplugues de Llobregat, Madrid

2023-11-20

Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

NCT06173518Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

DrugAUTO1

Autolus Limited

Phase 1

Barcelona, Madrid

2023-11-16

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356Non-Small Cell Lung Cancer (NSCLC)

DrugsLumakras·Sotorasib·Pembrolizumab

Amgen

Phase 3

750

Málaga, Seville, Zaragoza, Palma de Mallorca, Las Palmas de Gran Canaria, Santander, Valladolid, Barcelona

2023-11-16

Recruiting

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

NCT06095583Limited-stage Small Cell Lung Cancer (LS-SCLC)

DrugsTifcemalimab·Toripalimab

Shanghai Junshi Bioscience Co., Ltd.

Phase 3

756

A Coruña, Barcelona, Jaén, Madrid, San Sebastián, Zaragoza

2023-11-15

Active, closed

Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

NCT06042478Chronic Spontaneous Urticaria

DrugsOmalizumab·Remibrutinib

Novartis Pharmaceuticals

Phase 3

470

Granada, Barcelona, Córdoba, Las Palmas GC, Valencia

2023-11-15

Recruiting

Enhancing Quality of Life in Cancer Patients Through Tailored Nutrition Support: a Comprehensive Approach

NCT06628141Cancer

UOMi Cancer Center

Not applicable

120

Barcelona

2023-11-14

Recruiting

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

NCT05658640Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory

DrugsTrametinib·Cytarabine·Dexamethasone·Cyclophosphamide

Princess Maxima Center for Pediatric Oncology

Phase 1/2

Barcelona, Madrid, Valencia

2023-11-14

Active, closed

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

NCT06112379Breast Cancer

DrugsDato-DXd·Epirubicin·Xeloda·Olaparib

AstraZeneca

Phase 3

1,902

Barcelona, Granada, Hospitalet deLlobregat, Madrid, Santiago de Compostela, Seville, Zaragoza

2023-11-14

Active, closed

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

NCT06062420Neoplasms, Head and Neck

DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab

GlaxoSmithKline

Phase 2

316

Barcelona, Jaén, Madrid, Pozuelo de AlarcOn Madr, Salamanca, Santander, Valencia, Zaragoza

2023-11-14

Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

DrugsElironrasib·Cetuximab

Revolution Medicines, Inc.

Phase 1/2

534

Barcelona, Madrid, Pamplona, Seville, Valencia, Zaragoza

2023-11-14

Active, closed

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

NCT06075706Steroid-refractory Acute Graft-versus-host Disease

DrugMC0518

medac GmbH

Phase 2

Madrid, Pamplona, Barcelona, Málaga, Murcia, Valencia

2023-11-13

Recruiting

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

NCT05319353Cytomegalovirus (CMV)

DrugMaribavir

Takeda

Phase 3

Espluges de Llobregat, Horcajo de la Sierra, Málaga, Barcelona, Madrid

2023-11-13

Active, closed

Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

NCT05784012Head and Neck Squamous Cell Carcinoma

DrugsNiraparib·Dostarlimab·Cisplatin

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Phase 1/2

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Valencia

2023-11-13

Active, closed

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

NCT05870579Breast Cancer

DrugsGa-NeoB·Lu-NeoB·Ribociclib·Fulvestrant

Novartis Pharmaceuticals

Phase 1

L'Hospitalet de Llobregat, Barcelona, Madrid

2023-11-13

Active, closed

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

NCT06107413Unresectable Metastatic Colorectal Cancer

DrugsFolinic acid·Telisotuzumab Adizutecan·Fluorouracil·Irinotecan

AbbVie

Phase 2

280

Barcelona, Madrid, Valencia, Zaragoza

2023-11-12

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT06074588Non-small Cell Lung Cancer (NSCLC)

DrugsTaxotere·Sacituzumab tirumotecan·Pemetrexed·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

556

Barcelona, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Madrid, Málaga

2023-11-12

Active, closed

Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

NCT05890729Pulmonary Sarcoidosis

Xentria, Inc.

Phase 1/2

Barcelona, Seville

2023-11-10

Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

NCT06084481Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma

DrugsTelisotuzumab Adizutecan·Itraconazole·Bevacizumab

AbbVie

Phase 1

325

Badalona, Pamplona, Barcelona, Madrid, Málaga, Zaragoza

2023-11-09

Active, closed

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

NCT06097728Unresectable Pleural Mesothelioma

DrugsVolrustomig·Yervoy·Paraplatin·Ipilimumab

AstraZeneca

Phase 3

863

Barakaldo, Barcelona, Madrid, Oviedo

2023-11-09

Active, closed

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo

DrugRitlecitinib

Pfizer

Phase 3

1,571

Córdoba, Badalona, L'Hospitalet de Llobregat, Santiago de Compostela, Madrid, Barcelona, Valencia, Zaragoza

2023-11-08

Active, closed

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT05925803Systemic Sclerosis, Scleroderma

AstraZeneca

Phase 3

314

A Coruña, Barcelona, Madrid, Málaga, Valencia

2023-11-08

Active, closed

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

NCT05782907Ulcerative Colitis

DrugUpadacitinib

AbbVie

Phase 3

122

Ferrol, Esplugues de Llobregat, Barcelona, Málaga

2023-11-06

Active, closed

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

NCT06101134Melanoma

DrugsPhesgo·Relatlimab·Opdivo·Nivolumab

Bristol-Myers Squibb

Phase 2

100

Barcelona, Cartagena, Badalona, Cantabria, San Pedro Alcántara, Málaga, Seville

2023-11-06

Active, closed

TheraSphere With Durvalumab and Tremelimumab for HCC

NCT05063565Hepatocellular Carcinoma

Boston Scientific Corporation

Phase 2

100

Barcelona, Pamplona, Oviedo, Madrid, Valencia, Valladolid

2023-11-03

Recruiting

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

NCT06085833Breast Cancer

ARTIDIS AG

Not applicable

2,706

Barcelona

2023-11-02

Active, closed

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

NCT06054555Melanoma

DrugsOpdivo·Nivolumab

Amgen

Phase 3

633

Seville, Badalona, Cáceres, El Palmar, Barcelona, Madrid, Málaga, Valencia

2023-11-02

By invitation

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

NCT06066580Becker Muscular Dystrophy

Edgewise Therapeutics, Inc.

Phase 2

260

Barcelona, Donostia / San Sebastian, Valencia

2023-11-02

Recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

NCT05862012Relapsed/Refractory Multiple Myeloma

Ichnos Sciences SA

Phase 1

200

Salamanca, Badalona, Barcelona, Madrid, Pamplona

2023-11-01

Active, closed

Minimally Displaced Femoral Neck Fracture Pilot Study

NCT05947058Femoral Neck Fractures

University of Maryland, Baltimore

Not applicable

Barcelona

2023-11-01

Recruiting

Lesion Formation With Pulsed Field Versus Cryobaloon Ablation as Assessed by Cardiac Magnetic Resoncance

NCT06220006Atrial Fibrillation

Hospital Clinic of Barcelona

Not applicable

104

Barcelona

2023-11-01

Active, closed

A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development

NCT06055725Spasticity as Sequela of Stroke

Ipsen

Observational

1,057

Badalona, Barcelona, Madrid, Seville, Vigo, Zaragoza

2023-11-01

Recruiting

Unravelling the Impact of Radiofrecuency in Liver Surgery: the Key to Decrease Local Recurrence?

NCT05492136Liver Cancer, Cancer, Treatment-Related

Hospital del Mar

Not applicable

720

Barcelona

2023-11-01

Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT05696626Metastatic Breast Cancer

DrugsAbemaciclib·Fulvestrant

LeonaBio

Phase 3

600

Barcelona, Córdoba, Madrid, Málaga, Pamplona, Valencia

2023-10-31

Active, closed

Modulating Early-life Nutrition for Childhood Obesity Prevention

NCT06091917Infant Growth, Childhood Overweight

Fundació Sant Joan de Déu

Not applicable

Barcelona

2023-10-31

Recruiting

Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)

NCT05762211Transplant Complication

DrugPooled allogeneic fecal microbiotherapy

MaaT Pharma

Phase 2

387

Barcelona, Granada, Madrid, Majadahonda, Murcia, Pamplona, Salamanca, Santander

2023-10-31

Active, closed

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915Sjogrens Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

612

Badalona, Sabadell, Bilbao, Santander, Vigo, A Coruña, Barcelona, Córdoba

2023-10-27

Recruiting

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

NCT05918302Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms

Drugs177Lu-edotreotide·Everolimus

Grupo Espanol de Tumores Neuroendocrinos

Phase 3

170

Seville, L'Hospitalet de Llobregat, Santiago de Compostela, Madrid, Oviedo, Valencia, Barcelona

2023-10-27

Active, closed

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

NCT05899608Non-Small Cell Lung Cancer

DrugsIvonescimab·Pembrolizumab

Summit Therapeutics

Phase 3

1,600

Badajoz, Badalona, Barcelona, Girona, Jaén, Las Palmas de Gran Canaria, Lugo, Madrid

2023-10-26

Recruiting

Implementing PROMs and PREMs in Routine Clinical Care: Assessment of Requirements and Impact

NCT06272552PROMs, PREMs, Implementation Research, Impact Evaluation

Parc de Salut Mar

Not applicable

1,440

Barcelona

2023-10-25

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578Progressive Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,057

Badalona, Barcelona, Santander, Santiago de Compostela, Málaga, Madrid, Majadahonda, Oviedo

2023-10-25

By invitation

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

NCT06126380Kidney Transplant Rejection

DrugsTegoprubart·Tacrolimus

Eledon Pharmaceuticals

Phase 2

132

Barcelona

2023-10-25

Active, closed

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

NCT05949684Myelodysplastic Syndromes

DrugsEpoetin Alfa·Reblozyl·Luspatercept

Bristol-Myers Squibb

Phase 3

402

Barcelona, L'Hospitalet de Llobregat, Valencia, Granada, Madrid, Oviedo, Salamanca, Seville

2023-10-24

Active, closed

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

NCT05984277Metastatic Non-small Cell Lung Cancer

DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin

AstraZeneca

Phase 3

895

Alicante, Barcelona, Bilbao (Vizcaya), Madrid, Málaga, Palma

2023-10-24

Recruiting

DESTINY Breast Respond HER2-(Ultra)Low Europe

NCT05945732Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer, HER2-(Ultra)Low Expressing Breast Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Observational

2,295

Albacete, Alicante, Alzira, Barakaldo, Barcelona, Bilbao, Cadiz, Cáceres

2023-10-24

Recruiting

PLAI-AF Trial: Hybrid Endo-epicardial Partial Left Atrial Isolation vs. Endocardial Ablation in Patients With Persistent Atrial Fibrillation

NCT05723536Atrial Fibrillation, Persistent Atrial Fibrillation, Arrythmia

Hospital Clinic of Barcelona

Not applicable

Barcelona

2023-10-23

Active, closed

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 2

114

Barcelona, Madrid, Salamanca, Seville, Terrassa

2023-10-23

Recruiting

Evaluation of a New Treatment Program for Adolescents With Eating Disorders: MINERVA Program

NCT06431854Eating Disorders in Adolescence, Anorexia Nervosa, Bulimia Nervosa, Binge-Eating Disorder

Fundació Sant Joan de Déu

Not applicable

120

Barcelona

2023-10-23

Recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

NCT06084936Lymphoma

DrugsGlofitamab·Bendamustine·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 3

182

Cadiz, A Coruña, Barcelona, Murcia

2023-10-22

Active, closed

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

NCT06013969Generalized Pustular Psoriasis

DrugSpesolimab

LEO Pharma

Phase 4

Barcelona, Madrid

2023-10-22

Active, closed

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

NCT05598333Congestive Heart Failure

AskBio Inc

Phase 2

150

Barcelona, Pamplona, Madrid, Santiago de Compostela, Valencia

2023-10-20

Recruiting

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

NCT06026410Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)

DrugsAdagrasib·Cabozantinib

Kura Oncology, Inc.

Phase 1

300

Barcelona, Madrid, Seville

2023-10-18

Active, closed

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

NCT05968326Adenocarcinoma, Pancreatic Ductal

DrugsAutogene cevumeran·MFOLFIRINOX·Tecentriq·Atezolizumab

Genentech, Inc.

Phase 2

260

Badalona, Málaga, Pamplona/iruña, Oviedo, Barcelona, Madrid

2023-10-18

Active, closed

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06045806Multiple Myeloma

DrugsIdecabtagene vicleucel·Endoxan·Fludara·Cytoxan

Celgene

Phase 3

Badalona, L'Hospitalet Del Llobregat, Barcelona, Pamplona, Madrid, Salamanca, Valencia

2023-10-16

Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma

DrugObrixtamig

Boehringer Ingelheim

Phase 2

204

Barcelona, Madrid, Málaga, Valencia

2023-10-13

Active, closed

Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy

NCT05952206Coronary Artery Disease

Drug12-month DAPT

iVascular S.L.U.

Phase 3

2,312

A Coruña, Almería, Barcelona, Cáceres, Huelva, Jerez de la Frontera, Las Palmas de Gran Canaria, León

2023-10-13

Active, closed

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

NCT06095115Plaque Psoriasis

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

684

Alcorcón, Alicante, Barcelona, Bilbao, Madrid, Palma de Mallorca, Santiago de Compostela, Seville

2023-10-12

Active, closed

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

NCT06095102Plaque Psoriasis

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

311

Badalona, Barcelona, Esplugues de Llobregat, Granada, Madrid, Manises, Seville, Valencia

2023-10-12

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240Alopecia Areata

DrugUpadacitinib

AbbVie

Phase 3

1,500

L'Hospitalet de Llobregat, Fuenlabrada, Barcelona, Córdoba, Madrid, Valencia

2023-10-11

Recruiting

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

NCT06082037Lung Transplant Rejection

DrugsBelumosudil·Azithromycin

Sanofi

Phase 3

180

Santander, Barcelona, A Coruña, Majadahonda, Valencia

2023-10-10

Active, closed

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083Multiple Myeloma

DrugsCilta-cel·Bortezomib·Daratumumab·Lenalidomide

Stichting European Myeloma Network

Phase 3

759

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santiago de Compostela, Seville, Valencia

2023-10-10

Active, closed

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756Arteriosclerosis, Hypercholesterolaemia

DrugEnlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 3

14,550

Torrevieja, Córdoba, Málaga, Seville, Calella, Barcelona, Centelles, L'Hospitalet de Llobregat

2023-10-09

Active, closed

A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma

NCT05888844Cutaneous Squamous Cell Carcinoma

DrugINCB099280

Incyte Corporation

Phase 2

Badalona, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Seville

2023-10-09

Recruiting

SEAL™ME: Saccular Endovascular Aneurysm Lattice System Multicenter Enrollment Global Registry

NCT05880680Aneurysm, Aneurysm, Ruptured

Galaxy Therapeutics INC

Observational

200

Barcelona

2023-10-09

Active, closed

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

NCT06045689Myelodysplastic Syndromes

DrugsReblozyl·Luspatercept

Bristol-Myers Squibb

Phase 3

106

L'Hospitalet de Llobregat, Barcelona, Granada, Madrid, Ourense, Salamanca, Valencia

2023-10-05

Active, closed

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

5,511

A Coruña, Albacete, Alicante, Badalona, Barakaldo, Barcelona, Burgos, Castellon

2023-10-05

Recruiting

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

NCT06072131Peripheral T Cell Lymphoma

DrugsBelinostat·Pralatrexate·CHOP·Prednisone

Acrotech Biopharma Inc.

Phase 3

504

Bilbao, Moncloa-Aravaca, Pamplona, Barcelona, Madrid, Salamanca, Valencia, Zaragoza

2023-10-04

By invitation

A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT06044337Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 3

306

Valladolid, Córdoba, Majadahonda, Barcelona, Seville

2023-10-03

Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

NCT05755386IC-MPGN

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

106

Pamplona, Almería, Barcelona, Madrid, Salamanca

2023-10-02

Active, closed

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

NCT05888493Follicular Lymphoma (FL)

DrugTisagenlecleucel

Novartis Pharmaceuticals

Phase 3

109

Santiago Compostela, L'Hospitalet de Llobregat, Santander, El Palmar, Barcelona, Córdoba, Madrid, Salamanca

2023-10-02

Recruiting

Post-Market Clinical Follow Up Study With Navitor Valve

NCT06008080Aortic Stenosis

Abbott Medical Devices

Observational

1,000

Badajoz, Barcelona, Huelva, Las Palmas, Majadahonda, Málaga, Valencia

2023-09-29

Active, closed

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

NCT06047457Episodic Migraine

DrugsDysport·Botulinum toxin type A

Ipsen

Phase 3

751

Barcelona, Madrid, Málaga, Valencia

2023-09-29

Recruiting

APACE - Feasibility of Using Accelerometers to Measure Physical Activity in Cancer Patients on Early Phase Clinical Trials

NCT06868355Cancer

University of Manchester

Observational

Barcelona, Madrid, Pamplona, Valencia

2023-09-28

Recruiting

Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)

NCT06114004Sarcoma,Soft Tissue

DrugsSelinexor·Gemcitabine

Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas

Phase 2

Santa Cruz de Tenerife, Barcelona, Donostia / San Sebastian, Madrid, Murcia, Valencia, Zaragoza

2023-09-28

Recruiting

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

NCT05957367GIST

DrugRipretinib

Deciphera Pharmaceuticals, LLC

Phase 1/2

Barcelona, Madrid, Seville

2023-09-28

Active, closed

RCT to Evaluate STERN FIX Device as a Sternal Stabilization System in Patients After Sternotomy

NCT05953259Median Sternotomy

NEOS Surgery

Not applicable

Barcelona, Pamplona, Madrid, Seville

2023-09-27

Recruiting

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

NCT06043817Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation

Pierre Fabre Medicament

Phase 1/2

345

Logroño, Málaga, Barcelona, Madrid, Seville

2023-09-26

Recruiting

Radiofrequency Ablation for the Treatment of Post-knee Arthroplasty Chronic Pain.

NCT05920382Chronic Post-surgical Pain, Chronic Post Operative Pain, Chronic Knee Pain

Consorci Sanitari de l'Alt Penedès i Garraf

Not applicable

Barcelona

2023-09-25

Recruiting

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

NCT06079671Locally Advanced Cervical Cancer

DrugVolrustomig

AstraZeneca

Phase 3

800

A Coruña, Barcelona, Córdoba, Girona, Hospitalet deLlobregat, Madrid, Palma de Mallorca, Valencia

2023-09-22

Active, closed

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

NCT05911295Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Gemcitabine·Cisplatin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

412

Badalona, L'Hospitalet de Llobregat, Barakaldo, Santander, Majadahonda, Badajoz, Barcelona, L'Hospitaler de Llobregat

2023-09-22

Active, closed

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

NCT05822752Hepatocellular Carcinoma

DrugsLivmoniplimab·Budigalimab·Sorafenib·Lenvatinib

AbbVie

Phase 2

130

Santander, Córdoba, Majadahonda, Pamplona, Barcelona, Madrid, Seville, Zaragoza

2023-09-21

Active, closed

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

NCT05849610High-Risk de Novo Multiple Myeloma

DrugsTalquetamab·Teclistamab·Bortezomib·Daratumumab

PETHEMA Foundation

Phase 2

Badalona, Barcelona, Madrid, Murcia, Pamplona, Salamanca, Santander, Santiago de Compostela

2023-09-21

Active, closed

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

NCT06088290Leiomyosarcoma

DrugsLurbinectedin·Doxorubicin

PharmaMar

Phase 3

469

A Coruña, Barcelona, Madrid, San Cristóbal de La Laguna, Seville, Valencia, Zaragoza

2023-09-21

By invitation

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

NCT06075537Mucopolysaccharidosis II

DrugTividenofusp alfa

Denali Therapeutics Inc.

Phase 2/3

Barcelona

2023-09-20

Active, closed

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080Large B-Cell Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone

Hoffmann-La Roche

Phase 3

1,130

Santiago de Compostela, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid, Seville, Valencia

2023-09-18

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT06003426Idiopathic Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,255

Santander, Santiago de Compostela, Madrid, Majadahonda, Barcelona, Girona, Oviedo, Pamplona

2023-09-14

Active, closed

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

NCT05904886Hepatocellular Carcinoma

DrugsTiragolumab·Tecentriq·Avastin·Atezolizumab

Hoffmann-La Roche

Phase 3

687

Navarra, Pamplona/iruña, Oviedo, Barcelona, Jaén, Madrid, Valencia

2023-09-14

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic

DrugBelimumab

GlaxoSmithKline

Phase 2/3

300

Barcelona, Bilbao, Granada, Madrid, Seville, Valencia, VigoPontevedra

2023-09-13

Active, closed

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

NCT05869955Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis

DrugsZola-cel·Tocilizumab·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

270

Barcelona, Santander, Córdoba, Málaga

2023-09-13

By invitation

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

NCT05979441Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis

DrugEfgartigimod PH20

argenx

Phase 3

240

Barcelona, Madrid, Valencia

2023-09-12

Recruiting

International Prospective REgistry on Pre-pectorAl Breast REconstruction

NCT05817175Breast Cancer

European Breast Cancer Research Association of Surgical Trialists

Observational

1,236

Barcelona

2023-09-12

By invitation

Observational Study to Validate a Family Physician Echocardiography Training Programme

NCT07339007Heart Failure, Valvular Heart Diseases, Atrial Fibrillation (AF), Arterial Hypertension

Societat Catalana de Medicina Familiar i Comunitària, Assoc. (CAMFiC)

Observational

500

Barcelona

2023-09-12

Recruiting

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

NCT05722938Community-acquired Pneumonia

Biotest

Phase 3

590

Palma de Mallorca, Sabadell, Terrassa, Córdoba, Majadahonda, Pamplona, Oviedo, Barcelona

2023-09-09

Active, closed

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

NCT05846230Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 2

268

Barcelona, L'Hospitalet de Llobregat, Mérida, Pozuelo de Alarcón

2023-09-08

Recruiting

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239Metastatic Breast Cancer

DrugsPhesgo·Inavolisib

Hoffmann-La Roche

Phase 3

230

A Coruña, Barcelona, Madrid, Málaga, Seville

2023-09-08

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

NCT06047171Glomerulonephritis Rapidly Progressive

DrugsCyclophosphamid·Rituximab

Alentis Therapeutics AG

Phase 2

Barcelona, Lleida, Madrid, Málaga

2023-09-07

Recruiting

CONCEPTT Kids International Neurodevelopmental Outcomes Among Offspring of Women With Type 1 Diabetes

NCT05754567Neurocognitive Disorders

University of Manitoba

Observational

225

Barcelona

2023-09-07

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617Primary Biliary Cholangitis

DrugSeladelpar

Gilead Sciences

Phase 3

402

A Coruña, Alcorcón, Badalona, Barcelona, Córdoba, Málaga, Santander, Seville

2023-09-07

Recruiting

Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome

NCT05926505Post-Acute COVID-19 Syndrome, Post-Acute COVID-19, Long COVID

DrugAnakinra

Hellenic Institute for the Study of Sepsis

Phase 2/3

182

Barcelona

2023-09-06

Recruiting

Study of Personalized Allocation of Defibrillators in Non-ischemic Heart Failure (SPANISH-1)

NCT06055504Non-ischemic Dilated Cardiomyopathy

Consorcio Centro de Investigación Biomédica en Red (CIBER)

Not applicable

900

Santiago de Compostela, L'Hospitalet de Llobregat, Sabadell, A Coruña, Majadahonda, Oviedo, Alicante, Barcelona

2023-09-06

Recruiting

The ReTAVI Prospective Observational Registry

NCT05601453Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction

Institut für Pharmakologie und Präventive Medizin

Observational

250

Barcelona, León, Madrid, Oviedo, Vigo

2023-09-05

Active, closed

Deep Brain Stimulation Recovery in Treatment-Resistant Schizophrenia

NCT05337904Treatment-resistant Schizophrenia, Deep Brain Stimulation

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Not applicable

Barcelona

2023-09-01

Active, closed

Effectivenness and Implementation of an Intervention to Improve Primary Care Patient Safety

NCT05958108Patient Safety

Fundació d'investigació Sanitària de les Illes Balears

Phase 3

110

Granada, Palma de Mallorca, Barcelona, Madrid, Murcia, Salamanca, Pontevedra, Zaragoza

2023-09-01

Recruiting

Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and ICG in Patients With Epithelial Ovarian Cancer

NCT05937620Ovarian Epithelial Cancer

Fundacion Clinic per a la Recerca Biomédica

Not applicable

Barcelona

2023-09-01

By invitation

NON-INVASIVE BLOOD FLOW ASSESSMENT: Computational Tool for Measuring Arterial Flow From CT

NCT07155616Pancreatic Cancer, Vascular, Surgical Planning

Hospital Clinic of Barcelona

Observational

100

Barcelona

2023-09-01

Active, closed

The Effects on Physical Activity on Mitochondrial Function in Skin Fibroblasts in Patients with Parkinson's Disease.

NCT05963425Parkinson's Disease

University Ramon Llull

Not applicable

Barcelona

2023-09-01

Active, closed

Enlighten Study: The EV-ICD Post Approval Registry

NCT06048731Ventricular Arrhythmia, Tachycardia

Medtronic

Observational

1,000

A Coruña, Barcelona, Córdoba, Girona, Granada, Valencia

2023-09-01

Recruiting

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

DrugOlverembatinib

Ascentage Pharma Group Inc.

Phase 3

350

Badalona, Barcelona, Cáceres, Madrid, Santander, Seville, Valencia

2023-08-31

Active, closed

Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC

NCT06059001Metastatic Pancreatic Cancer

DrugsOMO-103·Nab-paclitaxel·Gemcitabine

Peptomyc S.L.

Phase 1

Barcelona, L'Hospitalet de Llobregat, Santander, Madrid, Málaga, Zaragoza

2023-08-31

By invitation

HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

NCT05883748Erythropoietic Protoporphyria

Disc Medicine, Inc

Phase 2/3

230

Barcelona

2023-08-31

Recruiting

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

NCT06016842Primary Biliary Cholangitis (PBC)

DrugElafibranor

Ipsen

Phase 3

276

Barcelona, Madrid, Majadahonda, Málaga, Pontevedra, Sabadell, Seville, Valencia

2023-08-31

Active, closed

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

DrugAficamten

Cytokinetics

Phase 3

500

A Coruña, Barcelona, Madrid, Málaga, Murcia, Palma de Mallorca, Salamanca, Seville

2023-08-31

Recruiting

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

NCT06064890Frontotemporal Dementia, FTD, FTD-GRN, Dementia, Frontotemporal

AviadoBio Ltd

Phase 1/2

Barcelona, Valencia

2023-08-30

Recruiting

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

NCT06270706Advanced or Metastatic Solid Tumor

DrugPembrolizumab

Pliant Therapeutics, Inc.

Phase 1

124

Barcelona, Logroño, Madrid

2023-08-30

Active, closed

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

NCT06052267Asthma

Teva Branded Pharmaceutical Products R&D LLC

Phase 3

2,772

Badalona, Barcelona, Córdoba, Madrid, Sabadell, Santiago de Compostela, Seville, Valencia

2023-08-30

Recruiting

Cardiovascular Risk Assessment in Young Women After Index Pregnancy With and Without Placental Complications

NCT07356817Cardiovascular (CV) Risk, Preeclampsia (PE), Fetal Weight

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Observational

1,260

Barcelona

2023-08-28

Active, closed

An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)

NCT06254482Huntington Disease

DrugVotoplam

Novartis Pharmaceuticals

Phase 2

144

Barakaldo, Barcelona, Burgos, Madrid

2023-08-25

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

NCT06023589Asthma

DrugTezepelumab

AstraZeneca

Phase 3

231

Badalona, Barcelona, Esplugues de Llobregat (Barc), Madrid, Sabadell, Valencia, Villarreal

2023-08-24

Recruiting

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

NCT06355934ATTR Amyloidosis

AstraZeneca

Observational

52,121

A Coruña, Barcelona, Bilbao, El Palmar, Huelva, Las Palmas de Gran Canaria, Madrid, Majadahonda

2023-08-21

Recruiting

The Preoperative Administration of ICG Improves Tumor Detection in Patients Undergoing Minimally Invasive Hepatic Resection Guided by Conventional Intraoperative Ultrasound.

NCT06398028Liver Tumor; Surgery

DrugIndocyanine Green

Hospital Universitari Vall d'Hebron Research Institute

Phase 4

173

Barcelona

2023-08-19

Recruiting

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor

Daiichi Sankyo

Phase 1/2

590

Barcelona, Madrid, Málaga, Pozuelo de Alarcón, Seville

2023-08-18

Recruiting

Motiva Flora® Aesthetic Breast Recon® Clinical Study

NCT06146231Mammaplasty, Breast Cancer, Poland Syndrome

Establishment Labs

Not applicable

Barcelona

2023-08-18

Recruiting

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

NCT05966493Persistent Corneal Epithelial Defect

Glaukos Corporation

Phase 2

Barcelona, Madrid, Seville, Zaragoza

2023-08-17

Active, closed

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

NCT05885555Primary Immune Thrombocytopenia (ITP)

DrugIanalumab

Novartis Pharmaceuticals

Phase 2

Barcelona

2023-08-16

Active, closed

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

NCT05771480Biliary Tract Cancer

DrugsAlbumin-Bound Paclitaxel·Teysuno·Durvalumab·Oxaliplatin

AstraZeneca

Phase 3

142

Barcelona, Madrid, Pamplona, Seville

2023-08-16

Recruiting

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

NCT05803941Prostate Cancer

DrugLu-PSMA

Novartis Pharmaceuticals

Phase 4

700

L'Hospitalet de Llobregat, Sabadell, Majadahonda, Barcelona, Madrid, Valencia

2023-08-14

Recruiting

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

NCT05997615Hormone-refractory Prostate Cancer

Astellas Pharma Global Development, Inc.

Phase 1

437

Barcelona, Logroño, Madrid, Málaga, Pamplona, Valencia

2023-08-10

Active, closed

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

NCT05909397Breast Cancer

DrugsVepdegestrant·Letrozole

Pfizer

Phase 3

Badalona, Barcelona, Jaén, Málaga, Granada, Madrid

2023-08-09

Recruiting

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

NCT05983432Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer

DrugIza-bren

SystImmune Inc.

Phase 1

540

Barcelona, Madrid, Piqueras, Seville

2023-08-08

Active, closed

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610Primary IgA Nephropathy

Hoffmann-La Roche

Phase 3

459

Lleida, Barcelona, Córdoba, Lugo, Madrid, Seville

2023-08-08

Recruiting

Coroflex® ISAR NEO PMCF Study

NCT05698732Coronary Artery Disease (CAD), Ischemic Heart Disease

Fundación EPIC

Observational

3,000

A Coruña, Badajoz, Badalona, Barakaldo, Barcelona, Cáceres, Ciudad Real, Huelva

2023-08-04

Recruiting

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

NCT05855200Colonic Neoplasms, Neoplasms, Colon

DrugsCapeox·Dostarlimab·Folfox

GlaxoSmithKline

Phase 3

892

Badajoz, BaracaldoVizcaya, Barcelona, Córdoba, Donostia / San Sebastian, Elche Alicante, Granada, Jaén

2023-08-01

Recruiting

Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II)

NCT05988645Colorectal Cancer, Colorectal Polyp, Colorectal Adenoma, Colorectal Adenomatous Polyp

MiWEndo Solutions S.L.

Not applicable

Barcelona

2023-08-01

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

DrugZipalertinib

Taiho Oncology, Inc.

Phase 2

220

Málaga, Barcelona, Jaén, Madrid

2023-07-31

Recruiting

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

NCT06068049Non-small Cell Lung Cancer

AstraZeneca

Observational

500

A Coruña, Alicante, Barcelona, C Rdoba, El Palmar, Girona, Granada, Jaén

2023-07-28

Recruiting

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

NCT05954312Advanced Solid Tumors

DrugsDocetaxel·Paclitaxel·Pembrolizumab

Vividion Therapeutics, Inc.

Phase 1

290

Barcelona, Madrid, Pamplona, Valencia

2023-07-28

Recruiting

Impact of Pleural Manometry on the Assessment and Treatment of Malignant Pleural Effusion: A Pilot Clinical Trial

NCT07120867Malignant Pleural Effusions (Mpe)

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Not applicable

Barcelona

2023-07-28

Recruiting

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

NCT05836324Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors

DrugsINCA33890·ADG126·Folfox·Cetuximab

Incyte Corporation

Phase 1

570

Barcelona, Madrid

2023-07-24

Active, closed

A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease

NCT06015841Parkinson Disease, Parkinson Disease 6, Early-Onset

DrugTriamcinolone

AC Immune SA

Phase 2

150

Barcelona, Donostia / San Sebastian, Madrid, Majadahonda, Pozuelo de Alarcón

2023-07-24

Active, closed

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

NCT05776004Pneumonia, Bacterial

Eagle Pharmaceuticals, Inc.

Phase 2

276

Barcelona, Madrid, Santiago de Compostela, Tarragona, Terrassa, Toledo, Valencia, Valladolid

2023-07-22

Active, closed

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,089

Barcelona, Pozuelo de Alarcón, Madrid, Málaga, Valencia

2023-07-19

Recruiting

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

NCT05797831Endometrial Cancer

DrugNavtemadlin

Kartos Therapeutics, Inc.

Phase 2/3

268

A Coruña, Barcelona, Galdakao, Jaén, Jerez de la Frontera, Las Palmas, León, Santiago de Compostela

2023-07-17

Recruiting

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

NCT05890677Lymphedema, Breast Cancer

University Hospital, Basel, Switzerland

Not applicable

280

Barcelona

2023-07-14

Active, closed

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

NCT05945823Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer

DrugsFutibatinib·Leucovorin·Irinotecan·Adrucil

Taiho Oncology, Inc.

Phase 2

Barcelona, Madrid

2023-07-13

Active, closed

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

NCT05851443Moderate to Severe Asthma

DrugsICS/LABA·Povorcitinib

Incyte Corporation

Phase 2

247

Barcelona

2023-07-11

Recruiting

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

NCT05980949Psychosis Associated With Alzheimer's Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1,000

Majadahonda, Málaga, Barcelona, Lleida, Madrid, Salamanca, Seville, Valladolid

2023-07-11

Active, closed

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

NCT05853367Metastatic Solid Tumors, Advanced Solid Tumors

DrugsCalderasib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1

L'Hospitalet de Llobregat, Madrid, Barcelona, Seville

2023-07-06

Active, closed

A Study of Zigakibart in Adults With IgA Nephropathy

NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy

DrugZigakibart

Novartis Pharmaceuticals

Phase 3

383

Manises, Barcelona, Girona, Lleida, Lugo, Madrid, Seville

2023-07-06

Recruiting

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement

DrugFutibatinib

Taiho Oncology, Inc.

Phase 2

120

Barcelona, Madrid, Pamplona

2023-07-05

Recruiting

MIcronized PROgesterone in Frozen Embryo Transfer Cycles

NCT05899010Infertility

DrugVaginal progesterone

Fundación Santiago Dexeus Font

Phase 3

1,020

Barcelona

2023-07-05

Recruiting

Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System

NCT04861805Symptomatic Aortic Stenosis

P+F Products + Features GmbH

Not applicable

267

Barcelona, Madrid, Valladolid, Majadahonda, Málaga, Oviedo

2023-07-03

Active, closed

A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group

NCT05937750Long Term Efficacy and Safety

Hansa Biopharma AB

Phase 3

150

Barcelona, Madrid

2023-07-03

Recruiting

A Prospective, Multicenter, Single-arm MAC-PD Cohort: a NTM-NET and ESGMYC Collaborative Study

NCT05906316Mycobacterium Avium Complex Pulmonary Disease

Radboud University Medical Center

Observational

100

Barcelona

2023-07-01

Active, closed

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT05785767Advanced Non-Small Cell Lung Cancer

DrugsFianlimab·Cemiplimab

Regeneron Pharmaceuticals

Phase 2/3

149

Santiago de Compostela, Palma, Barcelona, Majadahonda, Oviedo, Madrid, Málaga, Seville

2023-06-30

Recruiting

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

NCT05898399Advanced Solid Tumor, Metastatic Solid Tumor

DrugOlaparib

Artios Pharma Ltd

Phase 1/2

181

Granada, Valladolid, Barcelona, Cáceres, San Carlos, Cadiz, Madrid, Murcia

2023-06-30

Recruiting

Immersive Training on Metacognitive Capacities of Young People

NCT05899257Self, Self-Perception, Self Esteem

University of Barcelona

Not applicable

Barcelona

2023-06-30

Recruiting

Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

NCT06016946Friedreich Ataxia

Friedreich's Ataxia Research Alliance

Observational

3,000

Barcelona, Madrid

2023-06-28

Active, closed

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT05878769Chronic Obstructive Pulmonary Disease

DrugAstegolimab

Hoffmann-La Roche

Phase 3

2,000

Mérida, Palma de Mallorca, Santander, Santiago de Compostela, Torrejón de Ardoz, Benalmádena Costa, Alzira, Barcelona

2023-06-28

Active, closed

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

NCT05883644Advanced Hepatocellular Carcinoma

DrugsTremelimumab·Durvalumab

AstraZeneca

Phase 3

111

Barcelona, Córdoba, Madrid, Pamplona

2023-06-27

Active, closed

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

NCT05838768MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers

DrugsIrinotecan·Pembrolizumab

Novartis Pharmaceuticals

Phase 1

123

Barcelona, Madrid, Valencia

2023-06-27

Recruiting

A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations

NCT05788536Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

Regeneron Pharmaceuticals

Phase 1/2

Pamplona, Barcelona, Las Palmas de Gran Canaria, Madrid

2023-06-27

Active, closed

A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT05776472Paroxysmal Nocturnal Hemoglobinuria

DrugPegcetacoplan

Swedish Orphan Biovitrum

Observational

165

Badalona, Barakaldo, Barcelona, Bilbao, Donostia / San Sebastian, El Palmar, Huelva, Las Palmas de Gran Canaria

2023-06-26

Active, closed

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

NCT05672576Lupus Erythematosus, Systemic

DrugCenerimod

Viatris Innovation GmbH

Phase 3

451

Alcobendas, Barcelona, Colmenar Viejo, Madrid, Santiago de Compostela, Seville, Valencia, Valladolid

2023-06-26

Active, closed

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

NCT05601752Ovarian Cancer

USWM CT, LLC

Phase 2

Barcelona, Madrid, Valencia

2023-06-26

Active, closed

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

NCT05966480SLE

DrugEnvudeucitinib

Alumis Inc

Phase 2

408

A Coruña, Alicante, Barcelona, Seville, Valencia

2023-06-26

Active, closed

The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency

NCT05734196Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency

DrugINZ-701

Inozyme Pharma

Phase 1

Barcelona

2023-06-25

Recruiting

Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer

NCT06896890NSCLC (advanced Non-small Cell Lung Cancer), Stage IV Lung Cancer

Inhatarget Therapeutics

Phase 1/2

Barcelona, Madrid, Seville

2023-06-23

Active, closed

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

NCT05845814Metastatic Urothelial Carcinoma, Urothelial Neoplasms

DrugsPembrolizumab/Vibostolimab·Pembrolizumab/Favezelimab·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

390

Barcelona, Madrid

2023-06-23

Active, closed

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

NCT05827016Multiple Myeloma

DrugsIberdomide·Lenalidomide

Bristol-Myers Squibb

Phase 3

1,230

Barcelona, Cáceres, Las Palmas de Gran Canaria, Murcia, Oviedo, Valencia, Badalona, Madrid

2023-06-22

Recruiting

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

NCT05427370Coronary Artery Disease, Heart Failure Systolic

Sunnybrook Health Sciences Centre

Not applicable

754

Barcelona, El Palmar, Alicante, Pamplona

2023-06-22

Active, closed

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182Hidradenitis Suppurativa

DrugUpadacitinib

AbbVie

Phase 3

1,328

L'Hospitalet de Llobregat, Majadahonda, Manises, Barcelona, Granada, Madrid, Valencia

2023-06-21

Recruiting

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

NCT05789082Non-Small Cell Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 1/2

320

Badalona, Barcelona, Madrid, Seville, Valencia

2023-06-20

Recruiting

Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients

NCT05234723Cytomegalovirus Infections

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

100

Barcelona, Córdoba, Madrid

2023-06-19

Active, closed

Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma

NCT05830084Ewing Sarcoma

DrugRegorafenib

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1

Barcelona

2023-06-16

Active, closed

A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

NCT05811416Relapsing-remitting Multiple Sclerosis (RRMS)

Bristol-Myers Squibb

Observational

200

Barcelona

2023-06-14

Recruiting

Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute/Subacute Phase (Month 1 to 4)

NCT06107010Stroke, Acute, Stroke, Ischemic, Stroke, Subacute, Stroke Hemorrhagic

Wandercraft

Not applicable

Barcelona

2023-06-12

Active, closed

Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

NCT05817942Ulcerative Colitis

DrugFilgotinib

Alfasigma S.p.A.

Observational

509

Barcelona, Badalona, Las Palmas de Gran Canaria, Palma de Mallorca, Santiago de Compostela

2023-06-12

Recruiting

Multimodal Prehabilitation in Patients with Lung Cancer Undergoing Neoadjuvant Therapy

NCT05636969Non Small Cell Lung Cancer

Hospital Clinic of Barcelona

Not applicable

Barcelona

2023-06-10

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

NCT05753501Hematologic Cancer

DrugVenetoclax

AbbVie

Phase 1

135

Majadahonda, Barcelona, Madrid, Salamanca

2023-06-09

Recruiting

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

NCT05897320Episodic Migraine

DrugEptinezumab

H. Lundbeck A/S

Phase 3

315

Vigo, Barcelona, Madrid, Valencia

2023-06-08

Active, closed

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases

Alexion Pharmaceuticals, Inc.

Phase 3

165

A Coruña, Barcelona, Pamplona, Seville

2023-06-07

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862Breast Cancer

DrugsBupropion·Omeprazole·Alpelisib·Inavolisib

Hoffmann-La Roche

Phase 3

420

L'Hospitalet de Llobregat, Santiago de Compostela, San Cristóbal de La Laguna, Barcelona, Cáceres, Madrid, Málaga, Murcia

2023-06-07

Recruiting

Development and Validation of a Blood Test for Early Diagnosis of Colorectal Cancer

NCT06889883Colorectal Carcinoma, Advanced Adenomas (AA)

ADVANCED MARKER DISCOVERY S.L.

Observational

510

Zaragoza, Bilbao, Donostia / San Sebastian, Santander, Salamanca, Barcelona, Madrid, Oviedo

2023-06-06

Recruiting

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma

DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin

AstraZeneca

Phase 1/2

622

Barcelona, Madrid, Málaga

2023-06-05

By invitation

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

NCT05707949Migraine Prophylaxis

DrugAtogepant

AbbVie

Phase 3

650

Barcelona, Madrid, Seville, Valencia

2023-06-05

Recruiting

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

NCT05908409Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double Hit Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified

DrugIDP-121

IDP Discovery Pharma S.L.

Phase 1/2

Santander, Salamanca, Barcelona, Madrid, Murcia, Seville, Valencia, Zaragoza

2023-06-05

Active, closed

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT05869903Obesity, Overweight, Overweight or Obesity

DrugOrforglipron

Eli Lilly and Company

Phase 3

3,127

A Coruña, Ferrol, Almería, Málaga, Seville, Badalona, Barcelona, Valladolid

2023-06-05

Recruiting

Imlifidase Prior to Kidney Transplant in Highly Sensitised Children

NCT05753930Kidney Transplantation in Highly Sensitized Patients

DrugImlifidase

Hansa Biopharma AB

Phase 2

Barcelona

2023-06-02

Active, closed

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

NCT05607550Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 3

398

Málaga, A Coruña, Barcelona, Madrid, Valencia

2023-06-01

Active, closed

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

NCT05740566Small Cell Lung Cancer (SCLC)

DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan

Amgen

Phase 3

509

Málaga, Zaragoza, Barcelona, A Coruña, Majadahonda, Madrid

2023-05-31

Recruiting

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

NCT05714085Heart Failure, Left Ventricular Systolic Dysfunction

DrugVericiguat

Merck Sharp & Dohme LLC

Phase 2/3

342

Esplugues de Llobregat, Barcelona, A Coruña, Madrid, Seville

2023-05-31

Recruiting

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

NCT04954599Unspecified Adult Solid Tumor, Protocol Specific

DrugsAvelumab·Cemiplimab·Paraplatin·Ipilimumab

Maastricht University Medical Center

Phase 1/2

126

Barcelona

2023-05-30

Recruiting

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

NCT05765851Advanced Solid Tumor

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 1

128

Barcelona

2023-05-30

Active, closed

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05809531C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis

DrugPegcetacoplan

Apellis Pharmaceuticals, Inc.

Phase 3

100

Barcelona, Madrid, Valencia

2023-05-29

Active, closed

Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas

NCT05809830Advanced Soft-tissue Sarcoma

DrugsDoxorrubicin·LB-100·Doxorubicin

Grupo Espanol de Investigacion en Sarcomas

Phase 1/2

152

Barcelona, Madrid, Murcia, Valencia

2023-05-29

Recruiting

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

NCT05732831Locally Advanced Solid Tumor

DrugsTNG462·Keytruda·Pembrolizumab

Tango Therapeutics, Inc.

Phase 1/2

225

Barcelona, Madrid, Málaga, Seville

2023-05-26

Active, closed

GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.

NCT05674422Patients With Locally Advanced Rectal Cancer

Grupo Espanol Multidisciplinario del Cancer Digestivo

Observational

120

Badalona, Terrassa, Madrid, Barcelona, Girona, Valencia, Zaragoza

2023-05-26

Recruiting

Comparison of EVAR and ESAR for Infrarenal Aortic Aneurysms With a Wide Proximal Neck

NCT05484115Aortic Aneurysm, Abdominal

Rijnstate Hospital

Not applicable

300

Barcelona, Zaragoza

2023-05-26

Active, closed

PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin

NCT05810870Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer

DrugEribulin

MedSIR

Phase 2

Granada, Seville, Donostia / San Sebastian, Santander, A Coruña, Torrejón de Ardoz, Vigo, Barcelona

2023-05-24

Active, closed

Study of PYX-106 in Solid Tumors

NCT05718557Solid Tumor

Pyxis Oncology, Inc

Phase 1

Barcelona, Madrid, Valencia

2023-05-23

Recruiting

EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

NCT06923761Advanced Solid Malignancy

Grey Wolf Therapeutics

Phase 1/2

300

Barcelona, Madrid, Málaga, Pamplona, Valencia

2023-05-21

Active, closed

A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

NCT05908734Carcinoma, Non-Small-Cell Lung

DrugsCetrelimab·Amivantamab

Janssen Research & Development, LLC

Phase 1/2

Alicante, Barcelona, Madrid, Seville, Valencia

2023-05-18

Active, closed

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

NCT05663866Carcinoma, Non-Small-Cell Lung

DrugsMontelukast·Lazertinib·Amivantamab·Methotrexate

Janssen Research & Development, LLC

Phase 2

Barcelona, Cáceres, Jerez de la Frontera, L'Hospitalet de Llobregat, Madrid, Málaga, Palma de Mallorca, Santiago de Compostela

2023-05-18

Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

NCT05748171ACUTE LYMPHOBLASTIC LEUKEMIA

DrugInotuzumab Ozogamicin

Pfizer

Phase 2

100

Santiago de Compostela, Barcelona, Esplugues de Llobregat, Madrid, El Palmar, Seville, Valencia

2023-05-17

Recruiting

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT05442567Ulcerative Colitis, Crohn's Disease

DrugVedolizumab

Takeda

Phase 3

240

Sagunto, Barcelona, Madrid, Málaga, Seville

2023-05-16

Recruiting

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

NCT05765812Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III

DrugTemozolomide

Debiopharm International SA

Phase 1/2

116

Barcelona, Donostia / San Sebastian, Madrid, Pamplona, Valencia

2023-05-15

Recruiting

Evaluation of Navigation-Assisted TKA Using Mechanical vs. Restricted Kinematic Alignment

NCT05516381Knee Arthroplasty, Total

Exactech

Not applicable

148

Barcelona

2023-05-15

Active, closed

DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors

NCT05684276NSCLC, Pancoast Tumor

DrugsParaplatin·Taxol·Opdivo·Nivolumab

Fundación GECP

Phase 2

Alicante, Barcelona, Mataró, Bilbao, Cáceres, Jerez de la Frontera, Girona, Jaén

2023-05-12

Recruiting

A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

NCT05562466Asthma

DrugBudesonide

Novartis Pharmaceuticals

Phase 3

200

Esplugues, Sabadell, Barcelona, Córdoba, Madrid, Málaga

2023-05-11

Active, closed

Study of GS-4528 in Adults With Solid Tumors

NCT05840224Solid Tumor

DrugZimberelimab

Gilead Sciences

Phase 1

182

Barcelona, Madrid, Pamplona

2023-05-11

Active, closed

A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma

NCT05846516Pancreatic Ductal Adenocarcinoma

DrugEzabenlimab

Boehringer Ingelheim

Phase 1

Barcelona, Córdoba, Madrid

2023-05-11

Recruiting

SUPRAFLEX CRUZ PMCF Study ( rEpic05 )

NCT05617599Coronary Artery Disease (CAD), Ischemic Heart Disease

Fundación EPIC

Observational

508

Elche, A Coruña, Barakaldo, Barcelona, Castelló, Cáceres, Ciudad Real, Girona

2023-05-10

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer

DrugsAbraxane·Xeloda·Sacituzumab Govitecan·Taxol

Gilead Sciences

Phase 3

654

Barcelona, Bilbao, Córdoba, Elche, Jaén, Madrid, Salamanca, Santiago de Compostela

2023-05-08

Recruiting

Effectiveness and Implementation of a Digital Intervention for Pediatric Chronic Pain Co-designed With Patients

NCT05917626Chronic Pain

University of Malaga

Not applicable

195

Almería, Barcelona, Granada, Madrid, Cartagena, Málaga

2023-05-05

Active, closed

Phase III Study of AK112 for NSCLC Patients

NCT06396065Non-Squamous Non-small Cell Lung Cancer

DrugsIvonescimab·Pemetrexed·Carboplatin

Summit Therapeutics

Phase 3

420

A Coruña, Barcelona, Las Palmas, Lugo, Madrid, Majadahonda, Málaga, Seville

2023-05-04

Active, closed

Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease

NCT05755711Coronary Artery Disease

Shockwave Medical, Inc.

Observational

399

Santiago de Compostela, Barcelona, Córdoba, Madrid

2023-05-03

Active, closed

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

NCT05876754Cholangiocarcinoma

DrugIvosidenib

Servier Affaires Médicales

Phase 3

299

A Coruña, Barcelona, Córdoba, Elche, Madrid, Pamplona, Santander

2023-05-03

Recruiting

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT05850689Major Depressive Disorder

DrugLumateperone

Intra-Cellular Therapies, Inc.

Phase 3

470

Barcelona, Madrid, Sabadell, Zamora

2023-05-02

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

NCT05800665Advanced Prostate Cancer, Metastatic Prostate Cancer

Genentech, Inc.

Phase 1

210

Pamplona, Barcelona, Madrid

2023-05-02

Recruiting

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

NCT05711394Episodic Migraine

DrugAtogepant

AbbVie

Phase 3

450

Barcelona, Madrid, Seville, Valencia

2023-05-01

Recruiting

Transfemoral Transcatheter Aortic Valve Implementation at Hospital Without On-site Cardiac Surgery: Early Clinical Outcome in Patients With Prohibitive Surgical Risk.

NCT05886517Aortic Stenosis

AUSL Romagna Rimini

Not applicable

200

Barcelona

2023-05-01

Recruiting

Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia

NCT05741853Primary Progressive Aphasia, Dementia, Dementia, Frontotemporal, Alzheimer Disease

Stephanie Grasso

Not applicable

Barcelona

2023-05-01

Recruiting

Evaluation of the Epilepsy-related Quality of Life, Seizure-related Accidents and Validation of the Mjn-SERAS Solution in the Normalised Patient Environment with Real-World Data

NCT05845255Quality of Life, Epilepsy (treatment Refractory)

MJN Neuroserveis, S.L

Observational

130

Barcelona, Madrid, Pamplona

2023-05-01

Recruiting

The Ailliance Post-Market Clinical Study

NCT05856370Spinal Deformity, Spinal Degenerative Disorder, Spinal Fusion Failure, Spinal Trauma

Medtronic Spinal and Biologics

Not applicable

1,000

Barcelona

2023-05-01

Not yet open

Identification and Characterization of Genetic Variants in Hereditary Angioedema

NCT05833620Hereditary Angioedema With C1 Esterase Inhibitor Deficiency

Hospital Universitari Vall d'Hebron Research Institute

Observational

200

Barcelona, Madrid

2023-05

Active, closed

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

NCT05804045Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath

DrugPimicotinib

Abbisko Therapeutics Co, Ltd

Phase 3

Barcelona, Madrid

2023-04-27

Recruiting

Usefulness of PET-CT for Invasive Fungal Infection

NCT05688592Invasive Fungal Infections

Puerta de Hierro University Hospital

Observational

224

Majadahonda, Barcelona, Granada, Madrid, Málaga, Murcia, Oviedo, Salamanca

2023-04-27

Active, closed

Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies

NCT06459648Migraine

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Observational

350

Zaragoza, Donostia / San Sebastian, Santander, Valladolid, Barcelona, Madrid, Valencia

2023-04-26

Recruiting

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

NCT05818683Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer

DrugsJNJ-101556143·Lutetium Lu 177 vipivotide tetraxetan·Pasritamig·Cabazitaxel

Janssen Research & Development, LLC

Phase 1

300

Barcelona, Madrid

2023-04-26

Active, closed

FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

NCT05466799Locally Advanced Pancreatic Cancer

OncoSil Medical Limited

Phase 2

Barcelona, Madrid, Pamplona

2023-04-26

Active, closed

Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

NCT05705973Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease

Terumo Europe N.V.

Observational

3,000

Barcelona, Huelva, León, Salamanca, Seville

2023-04-25

By invitation

An Open-label Study of XEN1101 in Epilepsy

NCT05718817Focal Epilepsy, Tonic-Clonic Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

880

Barakaldo, Barcelona, Madrid, Málaga, Valencia, Valladolid

2023-04-25

Active, closed

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer

DrugsVolrustomig·Rilvegostomig·Lenvatinib·Gemcitabine

AstraZeneca

Phase 2

294

Barcelona, Madrid, Pamplona

2023-04-24

Active, closed

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

NCT05805501Renal Cell Carcinoma

DrugsTobemstomig·Tiragolumab·Axitinib·Keytruda

Hoffmann-La Roche

Phase 2

199

Córdoba, Barcelona, Madrid, Seville, Valencia

2023-04-21

Recruiting

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

NCT05685173B-cell Non-Hodgkins Lymphoma (B-NHL)

DrugOdronextamab

Regeneron Pharmaceuticals

Phase 1

107

Barcelona, Madrid

2023-04-20

Active, closed

A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

NCT05816252Non-small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Osimertinib·Carboplatin·Pembrolizumab

Klus Pharma Inc.

Phase 2

356

Majadahonda, Pozuelo de Alarcón, Barcelona, Málaga, Seville, Valencia

2023-04-19

Recruiting

Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments

NCT05769868Cirrhosis, Diabetes Mellitus, Oncologic Disorders

DrugEsmolol

Consorcio Centro de Investigación Biomédica en Red (CIBER)

Phase 3

1,000

Barcelona, Madrid, Salamanca, Valencia

2023-04-18

Recruiting

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

NCT05639647Gram-negative Bacterial Infections

Pfizer

Phase 2

Badalona, Esplugues de Llobregat, Madrid, Barcelona

2023-04-18

Active, closed

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

NCT05611931Endometrial Cancer

DrugSelinexor

Karyopharm Therapeutics Inc

Phase 3

257

Donostia / San Sebastian, Zaragoza, Badalona, Barcelona, Córdoba, Girona, Granada, Madrid

2023-04-18

Recruiting

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation

DrugsPanitumumab·Folfox·Cetuximab·Nab-paclitaxel

Institut de Recherches Internationales Servier

Phase 1/2

554

Barcelona, Madrid, Pamplona, Valencia

2023-04-18

Recruiting

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting

Weill Medical College of Cornell University

Not applicable

2,300

Elche, Barcelona, Madrid, Pamplona

2023-04-17

Active, closed

Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab

NCT05626855Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA

DrugApitegromab

Scholar Rock, Inc.

Phase 3

238

Barcelona, Valencia

2023-04-17

Recruiting

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139Breast Cancer, Solid Tumors, Adult

DrugsTersolisib·Imlunestrant·Tamoxifen·Exemestane

Eli Lilly and Company

Phase 1/2

880

Barcelona, Logroño, Madrid, Pozuelo de Alarcón, Reus, Seville

2023-04-17

Recruiting

Early Onset Colorectal Cancer Detection

NCT06342401Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Stage I

City of Hope Medical Center

Observational

400

Barcelona, Madrid, Salamanca, San Cristóbal de La Laguna

2023-04-15

Active, closed

A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction

NCT07304843Primary Biliary Cholangitis (PBC)

Umecrine Cognition AB

Phase 1/2

202

Barcelona, Madrid, Málaga, Pontevedra, Santander, Seville, Valencia

2023-04-14

Active, closed

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

NCT05645692Urothelial Cancer

DrugsTobemstomig·Tiragolumab·Atezolizumab

Hoffmann-La Roche

Phase 2

204

Barcelona, Madrid

2023-04-13

Recruiting

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

NCT05555589Neurotrophic Keratopathy

ReGenTree, LLC

Phase 3

Barcelona, Córdoba, Oviedo, Valencia

2023-04-11

Active, closed

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

NCT05757869Atrial Fibrillation

DrugsMilvexian·Apixaban

Janssen Research & Development, LLC

Phase 3

20,284

A Coruña, Alicante, Barcelona, El Palmar, Lleida, Madrid, Manises, Málaga

2023-04-11

Recruiting

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT05544019Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia

Schrödinger, Inc.

Phase 1

Barcelona, Madrid, Pamplona, Salamanca

2023-04-10

Recruiting

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

NCT05816382Narcolepsy Type 1

DrugTAK-861

Takeda

Phase 2/3

500

Vitoria-Gasteiz, Castellon, Alzira, Barcelona, Madrid

2023-04-05

Active, closed

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

NCT05692180Asthma

DrugBenralizumab

AstraZeneca

Phase 3

Badalona, Barcelona, Benalmádena, Esplugues de Llobregat

2023-04-05

Active, closed

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

NCT05785611Axial Spondyloarthritis

DrugFilgotinib

Alfasigma S.p.A.

Phase 3

495

Alicante, Barcelona, Bilbao, Córdoba, Madrid, Santander, Santiago de Compostela, Seville

2023-04-05

Active, closed

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma

AbbVie

Phase 1

L'Hospitalet de Llobregat, Barcelona, Madrid

2023-04-04

Recruiting

AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)

NCT05890716Cardiomyopathies, Cardiac Arrest, Cardiac Arrhythmias, Sudden Cardiac Death

Idoven 1903 S.L.

Observational

5,342

Barcelona, Ciudad Real, A Coruña, Madrid, Murcia, Pamplona, Santa Cruz de Tenerife, Valencia

2023-04-04

Active, closed

Evaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation

NCT05758909Aortic Valve Disease, Aortic Valve Stenosis, Heart Valve Diseases

Fundación EPIC

Observational

585

A Coruña, Alicante, Aravaca, Badalona, Barcelona, L'Hospitalet de Llobregat, Málaga, Oviedo

2023-04-04

Active, closed

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

NCT05723562Neoplasms, Rectal

DrugDostarlimab

GlaxoSmithKline

Phase 2

154

Barcelona, Granada, Madrid, Santander, Valencia

2023-04-03

Active, closed

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

NCT05794906Biochemically Recurrent Prostate Cancer

DrugDarolutamide

Bayer

Phase 3

985

Santiago de Compostela, Santander, Barcelona, Cadiz, Madrid, Málaga, Murcia, Seville

2023-04-03

Active, closed

Program to Avoid NSAIDs in Patients With Advanced Chronic Liver Disease

NCT07249294Advanced Chronic Liver Disease, Portal Hypertension Related to Cirrhosis

Parc de Salut Mar

Not applicable

Barcelona

2023-04-01

Active, closed

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

NCT05819359Parkinson's Disease

Bial R&D Investments, S.A.

Phase 2

237

Badalona, Barakaldo, Barcelona, Madrid, Seville

2023-03-31

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

NCT05727904Metastatic Melanoma, Unresectable Melanoma, Melanoma

DrugsLifileucel·Pembrolizumab

Iovance Biotherapeutics, Inc.

Phase 3

670

Santander, Málaga, Barcelona, Madrid, Pamplona, Seville, Valencia

2023-03-30

Active, closed

Sequent Extended Study

NCT05788432Coronary Artery Disease, Ischemic Heart Disease

Fundación EPIC

Observational

2,040

Alava, Alicante, Badajoz, Badalona, Barakaldo, Barcelona, Cadiz, Castelló

2023-03-28

Recruiting

Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)

NCT05885009Metastatic Prostate Cancer

SOLTI Breast Cancer Research Group

Observational

240

Barcelona

2023-03-28

Active, closed

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

NCT05601973Non Small Cell Lung Cancer

DrugsLazertinib·Zirabev·Amivantamab

ETOP IBCSG Partners Foundation

Phase 2

A Coruña, Alicante, Badalona, Barcelona, Bilbao, L'Hospitalet de Llobregat, Madrid, Valladolid

2023-03-27

Active, closed

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

NCT05714202Bladder Cancer

DrugsTAR-200·Cetrelimab

Janssen Research & Development, LLC

Phase 3

1,135

A Coruña, Algeciras, Barcelona, Cadiz, Castellon, L'Hospitalet de Llobregat, Lugo, Madrid

2023-03-23

Active, closed

Clinical Study Evaluating the Efficacy and Safety of CID v2.2 in Glaucoma Surgery

NCT05625958Glaucoma, Open-Angle, Glaucoma, Narrow Angle

Ciliatech

Not applicable

Barcelona, Madrid, Sabadell, Zaragoza

2023-03-23

Recruiting

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

NCT05259605Glioma, Glioneuronal Tumor, Choroid Plexus Tumor, Pineal Tumors

European Organisation for Research and Treatment of Cancer - EORTC

Observational

1,650

L'Hospitalet de Llobregat, Barcelona

2023-03-21

Active, closed

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

NCT05650879HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification

DrugsELVN-002·Fam-Trastuzumab Deruxtecan-Nxki·Trastuzumab emtansine·Trastuzumab deruxtecan

Enliven Therapeutics

Phase 1

198

Lleida, Seville, Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia

2023-03-20

Recruiting

Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study

NCT05692999Metastatic Non-squamous Lung Cancer

DrugsPemetrexed /m^2·Pembrolizumab

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

1,166

Barcelona, Madrid, Málaga, Seville

2023-03-20

Active, closed

Thoraflex Hybrid and Relay Extension Post-Approval Study

NCT05639400Thoracic Diseases, Aortic Aneurysm, Aortic Dissection, Thoracic Aortic Aneurysm

Vascutek Ltd.

Observational

352

Barcelona

2023-03-17

Active, closed

Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

NCT05612035Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease

Merck Sharp & Dohme LLC

Phase 2

129

Santander, Barcelona, Seville

2023-03-16

Recruiting

Stage II/III Colorectal Cancer Recurrence

NCT06314958Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Stage II, Colorectal Cancer Stage III

City of Hope Medical Center

Observational

400

Barcelona, Madrid

2023-03-15

Active, closed

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab

AbbVie

Phase 3

520

A Coruña, L'Hospitalet de Llobregat, Córdoba, Málaga, Pamplona, Barcelona, Girona, Madrid

2023-03-15

Active, closed

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

NCT05662397Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer

DrugCemiplimab

HotSpot Therapeutics, Inc

Phase 1/2

Barcelona, Madrid, Pamplona

2023-03-15

Recruiting

Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624

NCT05781217Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence, Androgen Deprivation Therapy

Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

Phase 3

534

L'Hospitalet de Llobregat, Fuenlabrada, Pozuelo de Alarcón, Barakaldo, Barcelona, Madrid, Tarragona, Valencia

2023-03-14

By invitation

Assessment of the Functional Capacity of Patients with Fibromyalgia: Clinical Validity

NCT06819930Fibromyalgia (FM), Work Ability, Physical Activity, Physical Functioning

University Ramon Llull

Observational

160

Barcelona

2023-03-14

Recruiting

A Study of PYX-201 in Advanced Solid Tumors

NCT05720117Solid Tumor, Advanced Solid Tumor

DrugPYX-201

Pyxis Oncology, Inc

Phase 1

330

Barcelona, Madrid, Valencia

2023-03-14

Recruiting

End-on Versus Parallel Radiofrequency Lesioning for Neurotomy of the Cervical Medial Branch Nerves

NCT05818774Neck Pain, Zygapophyseal Joint Arthritis

University Health Network, Toronto

Not applicable

Barcelona

2023-03-10

Active, closed

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

NCT05705349HIV-1 Infection

DrugsDOR/ISL·B/F/TAF

Merck Sharp & Dohme LLC

Phase 3

537

Elche, Badalona, Barcelona, L'Hospitalet de Llobregat,Barcelona, Madrid, Málaga

2023-03-08

Recruiting

Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma

NCT04128072Stage IB-IIB Cutaneous T-Cell Lymphoma

DrugMogamulizumab

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

Barcelona, Madrid

2023-03-07

Recruiting

A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

NCT05744921Paroxysmal Nocturnal Hemoglobinuria

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

202

Bilbao, Barcelona

2023-03-07

Active, closed

Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder

NCT05818943GRIN-related Disorders

DrugRadiprodil

GRIN Therapeutics, Inc.

Phase 1

Barcelona, Madrid

2023-03-07

Recruiting

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

NCT06511648Muscle-invasive Bladder Cancer

DrugErdafitinib

Spanish Oncology Genito-Urinary Group

Phase 2

Barcelona, A Coruña, Lugo, Madrid, Toledo, Valencia, Valladolid, Zaragoza

2023-03-07

Active, closed

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

NCT05635708Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer

DrugsGimistotug·Alcestobart·Nab-paclitaxel·Pemetrexed

BeiGene

Phase 2

400

Barcelona, Madrid, Seville

2023-03-07

Active, closed

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

NCT05526755Stage II-IIIB Non-small Cell Lung Carcinoma

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 2

188

Badalona, Barcelona, Bilbao, Granada, L'Hospitalet de Llobregat, Madrid, Seville, Valencia

2023-03-06

Recruiting

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

NCT05677971Alpha1-Antitrypsin Deficiency

DrugFazirsiran

Takeda

Phase 3

160

Barcelona, Málaga, Santander, Seville

2023-03-06

Recruiting

Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment

NCT05327062Cardiac Resynchronization Therapy, Chronic Heart Failure, Left Bundle-Branch Block

XSpline S.p.A.

Not applicable

150

Barcelona

2023-03-06

Active, closed

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

NCT05625399Melanoma

DrugsPhesgo·Relatlimab·Nivolumab

Bristol-Myers Squibb

Phase 3

579

A Coruña, Barcelona, Donostia / San Sebastian, Jaén, Madrid, Valencia, Badalona, Las Palmas de Gran Canaria

2023-03-06

Active, closed

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623Advanced Breast Cancer

DrugsVepdegestrant·Fulvestrant

Pfizer

Phase 3

624

A Coruña, Elche, Badalona, Barcelona, Bilbao, L'Hospitalet de Llobregat, Donostia / San Sebastian, Lleida

2023-03-03

Active, closed

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

NCT05639114Systemic Lupus Erythematosus

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

436

Santiago Compostela, Elche, Badalona, Santander, Barcelona, San Sebastian Reyes, Pamplona, Vigo

2023-03-02

Recruiting

High Definition Medicine for Solid Tumors Oncology

NCT06590506Metastatic Solid Tumor, Advanced Cancer

Centro Nacional de Investigaciones Oncologicas CARLOS III

Observational

300

A Coruña, Fuenlabrada, Palma de Mallorca, Pamplona, Seville, Barcelona, Cáceres, Madrid

2023-03-02

Active, closed

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

NCT05669755Cardiovascular Disease

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

7,101

Fuenlabrada, Alzira, Antequera, Barcelona, Castilleja de la Cuesta, Córdoba, Las Palmas de Gran Canaria, Madrid

2023-03-01

Active, closed

Testing a Nature-based Social Intervention on Loneliness: the RECETAS-BCN Trial

NCT05488496Loneliness

University of Vic - Central University of Catalonia

Not applicable

317

Barcelona

2023-03-01

Active, closed

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

NCT05201066Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

DrugsSpartalizumab·Decitabine·Azacitidine·Venetoclax

Novartis Pharmaceuticals

Phase 2

Badalona, Barcelona, Madrid

2023-02-28

Active, closed

Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)

NCT05593614Chemotherapy-induced Peripheral Neuropathy

AlgoTherapeutix

Phase 2

276

Barcelona, Córdoba, Jaén, Madrid, Reus, Valencia

2023-02-28

Active, closed

A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD

NCT05933200Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Ultragenyx Pharmaceutical Inc

Phase 3

Barcelona, A Coruña, Madrid

2023-02-28

Recruiting

The Safety and Feasibility of the eLym™ System

NCT05747196Heart; Decompensation, Congestive

WhiteSwell, Limited

Not applicable

Barcelona, Badalona, Madrid, Majadahonda, San Carlos, Valencia, Valladolid

2023-02-28

Recruiting

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

NCT05723198Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases

DrugBaricitinib

Eli Lilly and Company

Phase 3

595

Badalona, Barcelona, Bilbao (Bizkaia), Madrid, Valencia

2023-02-27

Active, closed

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma

DrugsTovorafenib·Carboplatin

Day One Biopharmaceuticals, Inc.

Phase 3

418

Barakaldo, Barcelona, Madrid, Seville, Valencia

2023-02-27

Recruiting

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

NCT05471856Solid Tumors

DrugEzabenlimab

Boehringer Ingelheim

Phase 1

Barcelona, Madrid, Valencia

2023-02-24

Recruiting

Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders

NCT05656469Mood Disorders, Anxiety Disorders, Psychotic Disorders

Parnassia Groep

Not applicable

2,500

Barcelona

2023-02-23

Active, closed

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

NCT05548127Breast Cancer

DrugsVepdegestrant·Abemaciclib

Pfizer

Phase 1/2

Barcelona, Madrid, Pamplona, Seville

2023-02-23

Active, closed

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

NCT05469360Alzheimer Disease, Mild Cognitive Impairment

Novartis Pharmaceuticals

Phase 1

Valencia, Barcelona

2023-02-23

Recruiting

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

NCT05651932Multiple Myeloma, Myeloma, Myeloma Multiple

DrugsMezigdomide·Carfilzomib·Pomalidomide·Dexamethasone

K36 Therapeutics, Inc.

Phase 1

165

Pamplona, Barcelona, Madrid, Salamanca

2023-02-22

By invitation

An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects

NCT05594992Mucopolysaccharidosis II

DrugJR-141

JCR Pharmaceuticals Co., Ltd.

Phase 3

Barcelona

2023-02-22

Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT05503797Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors

Fore Biotherapeutics

Phase 2

254

Santiago de Compostela, Barcelona, Madrid, Seville, Valencia

2023-02-21

Active, closed

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

NCT05676931Advanced Non-Small Cell Lung Cancer

DrugsQuemliclustat·Domvanalimab·Zimberelimab·Docetaxel

Gilead Sciences

Phase 2

400

Barcelona, Las Palmas de Gran Canaria, Lugo, Málaga, Seville, Valencia

2023-02-21

Active, closed

VIATORR Device Registry

NCT05661331Chronic Liver Disease

W.L.Gore & Associates

Observational

196

Barcelona

2023-02-21

Recruiting

Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation

NCT05952583Twin; Pregnancy, Affecting Fetus or Newborn, Fetal Growth Retardation, Twin Monochorionic Diamniotic Placenta, Twin Diseases

Leiden University Medical Center

Observational

274

Barcelona

2023-02-17

Active, closed

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

NCT05702034Ischemic Stroke; Ischemic Attack, Transient

DrugMilvexian

Janssen Research & Development, LLC

Phase 3

12,523

A Coruña, Albacete, Alicante, Badalona, Barakaldo, Barcelona, Córdoba, Girona

2023-02-15

Recruiting

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

NCT05683418HR+/HER2-negative Breast Cancer

DrugsRibociclib·Palbociclib·Fulvestrant

Totus Medicines

Phase 1

241

Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Valencia

2023-02-15

Active, closed

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

NCT05711940Treatment Resistant Depression

DrugPsilocybin

COMPASS Pathways

Phase 3

572

Barcelona, Madrid, Sant Boi de Llobregat, Valladolid, Zamora

2023-02-14

Active, closed

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

NCT05722015Metastatic Non-small Cell Lung Cancer

DrugsPegylated filgrastim·Pembrolizumab Formulated with Berahyaluronidase Alfa·Filgrastim·Taxol

Merck Sharp & Dohme LLC

Phase 3

377

Santiago de Compostela, Madrid, Barcelona, Huelva

2023-02-14

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/barcelona?page=4

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,238 of those studies with a site in Barcelona.

How many clinical trials are recruiting in Barcelona?

1,669 of the 3,238 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 132 have not yet opened recruitment, 1,365 are active but closed to new participants, and 72 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.